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Submicroscopic structural genomic variation includes copy number 
variation (CNV) that can result changes in DNA dosage, and the impacts 
can be observed on common disease, metabolism, and heritable traits 
such as colour vision and rhesus blood group. Human beta-defensins form 
a cluster of at least seven genes on human chromosome 8p23.1, with a 
diploid copy number commonly ranging between 2 and 7 copies. They 
encode small secreted antimicrobial peptides with cytokine-like properties 
which are found expressed at high levels in psoriasis patients, and copy 
number at this locus has been found to be associated with inflammatory 
ERZHOGLVHDVHSDUWLFXODUO\FRORQLF&URKQ¶VGLVHDVH 
 
The focus of this thesis has been divided into two studies; looking for the 
origin of diversity at the human beta-defensins copy number, and 
development of a multiplex PRT measurement system for accurately typing 
the beta-defensin region in large case association study.  
 
The origin of diversity at the human beta-defensin copy number has been 
followed by using segregation in CEPH families. Three out of 416 meiotic 
transmissions changed the copy number by simple allelic recombination 
between two distinct loci for these genes. Deducing haplotype copy 
number from microsatellite and multiallelic length polymorphism have 
allowed this study to map the beta-defensin repeats in two locations at the 
original location distally REPD and about 5 Mb away at proximally REPP. 
We have demonstrated our multiplex PRT system is a powerful technique 
to determine the association of the beta-defensin JHQHVLQ&URKQ¶VGLVHDVH
even though we did not produce any convincing support for associations 
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Chapter 1: Introduction 
 
1.1: Genome variation  
Genome variations are differences in the sequence or copy number of 
DNA from one individual to another. Human genetic variation can be 
catalogued into large-scale variation involving more than 3 Mb which may 
be detectable at a microscopic (cytogenetic) level, and smaller 
(submicroscopic) scale variation which involves less than 3 Mb of DNA and 
includes the highly abundant copy number variants (CNVs) and single 
nucleotide polymorphism (SNP) variants. This field began from early 
research on human genetic diversity through cytogenetic approaches, 
which involved large-scale microscopic chromosome number and 
structural variation. Nowadays, as technology has advanced to resolve 
different classes of submicroscopic structural variation, research into 
variation has become one of the major efforts in human genetics, since 
these genetic differences are also found to play a crucial role in 
susceptibility to both inherited and infectious diseases. Furthermore, study 
on genetic diversity has allowed scientists to examine how different 
individuals can have a different response when affected by a disease, 
which will facilitate development of a specific treatment. Consequently, 
knowledge of human genetic diversity is a fundamental key to establish a 
link between genomic variation and phenotypic differences.  
 
 2 
1.1.1: Numerical chromosomal variation and its consequences  
Genetic differences in the human genome were first observed in the 
quantity and structure of chromosomes. These chromosomal variations 
were often associated with phenotypes in specific human disorders and 
could be seen by light microscopy in conventional cytogenetics, 
subsequently developed into the high-resolution chromosome banding 
techniques and fluorescence in situ hybridisation (FISH). These 
abnormalities can involve either an extra haploid set (n or 23 
chromosomes) or sets of the chromosome to the normal diploid set (2n or 
46 chromosomes) which is known as polyploidy, or an abnormal number of 
an individual chromosome (aneuploidy). Triploidy (3n) is one of the 
commonest chromosomal abnormalities seen in humans and is usually 
lethal during development, whereas tetraploidy (4n) is rarer than triploidy 
and always lethal. Polyploidy could be caused by the failure of meiosis in 
the germ cell (triploidy) or failure of the first cleavage division during 
mitosis which the DNA has replicated to give four chromosomes, but cell 
division failed to function normally (Jack, 1999; Peter and Ellard, 2007). 
The numerical chromosomal abnormalities are a relatively common 
occurrence in which the most obvious is trisomy of chromosome 21 
'RZQ¶VV\QGURPH(Lejeune et al., 1959) or of the sex chromosomes (for 
example 47,XXX, 47,XXY, or 47,XYY) (Jacobs et al., 1997).  
 
Aneuploidy may involve loss of a chromosome pair (nullisomy) or single 
chromosome (monosomy); or gain of a chromosome pair (tetrasomy) or 
 3 
single chromosome (trisomy). Whole chromosome trisomy commonly 
results from meiotic or mitotic non-disjunction events. Examples of a 
condition caused by trisomy of autosomal chromosomes are Down¶V
syndrome (Lejeune et al., 1959), also known as Trisomy 21, (an individual 
with Down¶V syndrome has three copies of chromosome 21, rather than 
two); trisomy of chromosome 18 (GZDUG¶V V\QGURPH (Edwards et al., 
1960) and trisomy chromosome 13 ZKLFK LVNQRZQDV3DWDX¶VV\QGURPH 
(Patau et al., 1960)'RZQ¶VV\QGURPHLVWKHPRVWFRPPRQDQGFRPSDWLEOH
with survival to adulthood; it occurs in about every 700 live births and is 
much more common with older mothers. Individuals with this syndrome are 
characterized by marked hypotonia (low muscle tone) and a constellation 
of characteristic facial features. They tend to have a lower than average 
cognitive ability, often ranging from mild learning difficulties to severe 
mental disability, and a high frequency of congenital heart disease 
(Korenberg et al., 1994).  
 
Furthermore, in contrast to the autosomes, having an additional sex 
FKURPRVRPH DV IRXQG LQ V\QGURPHV VXFK DV .OLQHIHOWHU¶V V\QGURPH 
(47,XXY) (Jacobs and Strong, 1959), causes relatively few problems and is 
compatible with normal lifespan. Autosomal monosomies are usually lethal 
during early embryonic development, but loss of a sex chromosome is less 
deleterious. 7XUQHU¶VV\QGURPH is an example of monosomy, in which an 
individual is female phenotypically but is born with only one sex 
chromosome, an X chromosome which is maternally derived with one of  
 4 
#the paternal  X or Y chromosome (45,X) lost either in meiosis or early 
embryogenesis (Jacobs et al., 1997)  .OLQHIHOWHU¶V V\ndrome is the most 
common disorder affecting the sex chromosomes described in humans, 
and occurs in one of every 500 male births. Most affected males are 
infertile and have some reduction in speech and language ability. 
Meanwhile the typical clinical features of a female patient with 7XUQHU¶V
syndrome are congenital webbed neck and deformity of the elbow; they 
have a variable phenotype, which includes short stature, ovarian failure, 
specific neurocognitive deficits and anatomical abnormalities (Sybert and 
McCauley, 2004). The incidence of this syndrome is found in one out of 
3000 live female births. It is likely that the characteristic clinical phenotypes 
associated with expand monosomies and trisomies of chromosomes relate 
to a relative gene dosage effect.    
 
1.1.2: Structural chromosomal variation and its consequences 
A number of cytogenetically visible chromosomal rearrangements 
(structural chromosomal variation) have been identified. An example of  a 
chromosome structural abnormality is a rearrangement resulting in a 
translocation event between two acrocentric chromosomes that fuse near 
the centromere region with loss of the short arms; such Robertsonian 
translocations have been seen involving all combinations of acrocentric 
chromosomes (chromosomes 13, 14, 15, 21 and 22). Reciprocal 
translocation may result from single breaks in any of two non-homologous 
chromosomes. The karyotype of Robertsonian translocations is left only 
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with 45 chromosomes since two chromosomes have fused together. There 
may be a balanced translocation in which there is no overall loss or gain of 
genetic material so that carriers of this balanced translocation typically 
have no adverse effects except relating to reproduction where infertility, 
recurrent spontaneous abortion, and risk of chromosomal imbalance 
among offspring can occur. These structural abnormalities may be 
constitutional involving for example recombination between mispaired 
chromosomes in the meiotic steps preceding gamete formation, or be 
acquired and arise in somatic cells secondary to exogeneous or 
endogeneous agents causing double-stranded DNA breaks.  
 
Other large scale structural variations discovered within a single 
chromosome or homologous pair of chromosome could be classified into 
deletions, microdeletions, duplications, inversions, isochromosomes and 
marker chromosomes. Genomic disorders are a group of genetic diseases 
which can arise from such chromosomal rearrangements which results in  
a gain, loss or disruption of dosage-sensitive genes (Lupski, 1998). There 
is clinical and phenotypic diversity for genomic disorders based on the 
actual genes and the number of genes that are deleted, and most are 
involved with mental retardation and congenital malformations. Cri du Chat 
and Wolf-Hirschhorn syndromes are two common examples of deletions 
involving chromosome 5p and 4p respectively. Microdeletion from paternal 
15q11.2-q13 is a main cause of Prader-Willi syndrome (PWS) and 
Angelman syndrome (AS) involves the maternal deletion of chromosome 
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15q11.2-q13 (Nicholls, 1993). PWS and AS represent the classical 
imprinting disorders in humans due to deletion of the paternal copies of the 
imprinted SNRPN gene and of maternal copies of the imprinted UBE3A 
gene respectively (Glenn et al., 1997).  
 
Inversion is also one of the possible structural variations in our genome 
and is defined as a variant in which DNA is reversed in orientation with 
respect to the rest of chromosome (Figure 1). Pericentric inversions 
include the centromere, whereas paracentric inversions do not involve the 
structure of the centromere. These abnormalities may not be associated 
with any phenotypic consequences but inversions of segmentally 
duplicated olfactory receptor genes at 4p16.1 and 8p23.1 have been 
associated with having offspring carrying a recurrent unbalanced 
translocation (Giglio et al., 2002). Isochromosomes occur when the 
centromere is divided transversely, instead of longitudinally in which one 
arm is lost and replaced with an exact copy of the other arm. It is found in 
7XUQHU¶V V\QGURPH DV D PRsaic cell line along with a 45,X cell line. A 
marker chromosome (mar) is a structurally abnormal chromosome of which 
the origin is not clear. The significance of a marker is hugely variable as it 
depends on what material is contained within the marker. Nevertheless, 
structurally abnormal variants as described above including translocations, 
inversions, deletions and duplications at the chromosome level, are 
identified less frequently than aneuploidies. Thus, their numbers might be 
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underestimated particularly with respect to the submicroscopic structural 
variation.  
 
1.1.3: Submicroscopic structural variation and its consequences 
Besides changes at the cytogenetic level, human genetic variation also 
involves structure of the DNA sequence on the chromosome known as 
submicroscopic structural variation. Extensive studies have been 
performed on polymorphic variation in the genome structure because of 
the ability to analyze duplication and deletions using hybridization 
techniques such as Southern blot hybridisation. Variation also can involve 
either only one base or many bases and can occur at any point in a DNA 
sequence. From these changes, there are numerous types of DNA 
variation, ranging from Single Nucleotide Polymorphisms (SNPs) to larger 
structural alterations such as copy number variants and inversions (Iafrate 
et al., 2004; Sebat et al., 2004; Khaja et al., 2006). If the two strands of a 
chromosome are thought of as nucleotides threaded on a string, then, for 
example, a string can break, and the order of the beads can vary. One or 
more nucleotides may be changed, added, or removed. These structural 
rearrangements can be called polymorphisms if they are sufficiently 
frequent in the population, and can in principle involve insertions, deletions, 
copy number variants (CNVs) due to deletion or duplication, inversion or 
translocation, based on the changes of DNA nucleotides with respect to 
the reference genome as illustrated in figure 1. Most cases of genomic 
disorders result from such submicroscopic structural variation, but some of 
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these structural variants arise among healthy individuals and some may 
contribute to susceptibility to disease. 
  
 
Figure 1: Illustration of the examples of DNA variation involving structural 
rearrangements of one or more regions. 
 
Among types of small-scale genetic variation, insertions and deletions 
(indels) are second commonest in the human genome. Indels have 
collectively been described as gain or loss of one or more contiguous 
nucleotides in genomic sequence when compared to a reference or 
ancestral sequence. The extent of indel polymorphism is becoming 
apparent with an estimated 1.5 million indels in human populations (Mills et 
al., 2006). Furthermore, two studies have used the HapMap data on family 
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trios to identify copy number polymorphisms (CNPs) (Conrad et al., 2006; 
McCarroll et al., 2006). In addition, Conrad et al. (2006) have found that 
deletions of 5 kb and larger are extremely widespread in the human 
genome and when a deletion is transmitted from parent to offspring, the 
child will show a null genotype or a genotype violating the rules of 
mendelian inheritance (Conrad et al., 2006). Other investigators have used 
an array comparative genomic hybridization approach to compare 24 
unrelated individuals with the reference human genome sequence (Hinds 
et al., 2006). Hinds and colleagues (2006) found 215 deletions ranging in 
size from 70 bp to 7 kb.  
 
Tandem repeat DNAs, for example minisatellites and microsatellites with 
repeat size ranging from 2 bp to 1000 bp also contribute to variation in the 
human genome. Variable length, which is based on numbers of repeating 
units, makes them highly informative as genetic markers of diversity. 
Satellite DNA comprises very long arrays of tandem repeats typically 100 
kb to several megabases in size and mainly forms the component of 
functional centromere, heterochromatin in pericentromeric and telomeric 
regions, and in the short arms of the acrocentric chromosomes. 
Minisatellite DNA arrays are of intermediate size and typically span 
between 100 bp and 20 kb with each repeat unit between 6 and 100 bp in 
length. Meanwhile, microsatellite DNA comprises short arrays less than 
100 bp in size, made up of simple tandem repeats 1 ± 6 bp in length. Each 
variant is inherited allowing them to be used for personal or parental 
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identification. Therefore, analysis of their length is useful in genetics and 
biology research, forensics, and DNA fingerprinting. Tandem repeats 
including minisatellite and microsatellite have been associated with a 
number of diseases and phenotypic conditions (Armour, 2006). For 
example polymorphism in expanded arrays of the triplet (CCG) upstream 
of the FMR1 gene causes fragile-X syndrome by reducing FMR1 
transcription (Pieretti et al., 1991) DQG+XQWLQJWRQ¶VGLVHDVH LVFDXVHGE\
the expansion of tandemly repeated CAG (glutamine) codons in the coding 
sequence, associated with gain of function (Macdonald et al., 1993). 
Polymorphism of tandem repeats within transcribed sequences for 
example, interactions of the expanded (CUG)n in RNA molecules 
transcribed from the DMPK gene with specific RNA binding proteins is 
known to modulate disease and can effect changes in the protein products 
of genes, leading to diseases such as myotonic dystrophy (Machuca-Tzili 
et al., 2005). Meanwhile, one of the earliest and best known minisatellite 
polymorphisms was found upstream of the insulin gene, where shorter 
alleles were associated with increased risk of type 1 diabetes (Bennett et 
al., 1995). These polymorphisms can arise from events such as unequal 
crossover, replication slippage or double-strand break repair.  
 
Certain features of genomic architecture, notably highly homologous low 
copy repeats (LCRs), predispose to chromosomal rearrangements through 
non-allelic homologous recombination (NAHR) and are the origin of a 
diverse group of genetic diseases (genomic disorders) (Lupski, 1998). The 
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term low copy repeats (LCRs) was used by Bernice Morrow following her 
studies of DiGeorge syndrome rearrangement breakpoints (Edelmann et 
al., 1999)6XEVHTXHQWO\WKHWHUP³VHJPHQWDOGXSOLFDWLRQV´6'VZDVILUVW
introduced by Evan Eichler (Bailey et al., 2001; Bailey et al., 2002) to 
explain his observations from genome wide studies. SDs are blocks of 
DNA ranging from 1-400 kb in length that occur at multiple sites within the 
genome and typically share a high level (>90%) of sequence identity 
(Eichler, 2001) and in total comprise about 5% of the human genome 
(Bailey et al., 2002). Some of the block sequences of SDs may be 
duplicated to multiple locations within a single chromosome, termed 
intrachromosomal duplication, and others might be located on non-
homologous chromosomes termed inter or transchromosomal duplication 
(Sharp et al., 2006). SDs are found interspersed throughout the genome 
and tend to cluster at pericentromeric and subtelomeric regions (Sharp et 
al., 2006). These features of SDs have considerable implications for 
human disease, evolution and other structural variation, as they provide a 
substrate for structural rearrangements resulting in the deletion, duplication 
or inversion of the intervening sequence by non-allelic homologous 
recombination (NAHR) (Sharp et al., 2006). Many studies have suggested 
that segmental duplications frequently mediate polymorphic rearrangement 
of intervening sequences (Iafrate et al., 2004; Sebat et al., 2004; McCarroll 
et al., 2006), and in addition they are often themselves variable in copy 
number (Sharp et al., 2005), which could certainly be generated by NAHR.  
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Colour vision variation (Nathans et al., 1986; Vollrath et al., 1988) and 
Rhesus (Rh) blood groups were shown to result from this kind of 
rearrangement (Sharp et al., 2006).  High sequence identity between those 
duplicated genes, for example in OPN1LW µRSVLQ ORQJ-wave-VHQVLWLYH¶
for the red photopigment) and OPN1MW µRSVLQPHGLXP-wave-VHQVLWLYH¶
for the green photopigment) genes, has predisposed to frequent NAHR 
leading to red-green colour vision defects of variable severity affecting up 
to 8% of male north Europeans (Deeb, 2004). Unequal crossing over which 
involves two highly homologous regions flanking the RHD gene known as 
rhesus boxes has also mediated the gene rearrangement for this gene 
(Wagner and Flegel, 2000). A further example is the alpha globin gene 
cluster, containing two highly homologous genes HBA1 and HBA2, which 
also highlights the occurrence of gene duplication. Unequal crossing over 
is thought to be involved with the occurrence of duplication or deletion of 
the HBA genes and then provides examples of copy number variation. 
Normal humans usually have four alpha-JORELQJHQHVĮĮĮĮWZRRQHDFK
chromosome. Individuals from different ethnic backgrounds have been 
reported having one chromosome with triplicated alpha-globin loci 
(Goossens et al., 1980). Most alpha thalassemia disease involves with 
deletion of one or both alpha-globin genes (Higgs et al., 1989) which 
results from unequal crossing over at meiosis due to extremely similar 
sequences within the gene cluster.  
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Further examples of recurrent submicroscopic structural variants that are 
involved with genomic disorders include Charcot-Marie-Tooth disease type 
1A (CMT1A) and hereditary neuropathy with liability to pressure palsy 
(HNPP) resulting from reciprocal duplication and deletion, respectively 
(Lupski, 2009). Individuals with three copies of the PMP22 gene (encoding 
a myelin protein) have CMT type 1A disease, and deletion of the gene is 
associated with HNPP. This region is flanked by complex low copy repeat 
sequences where reciprocal recombination events can occur if 
misalignment of the homologous chromosomes involving the region 
happened (Reiter et al., 1996; Reiter et al., 1998). Pelizaeus-Merzbacher 
disease is one of the examples of non-recurrent duplication, which is seen 
associated with the dosage sensitive proteolipid protein 1 gene (PLP1) at 
chromosome Xq22 (Lee et al., 2007).    
 
An example of large inversion that arises from non-allelic homologous 
recombination involving highly homologous low copy repeat regions (Shaw 
and Lupski, 2004) is on the long arm of chromosome 17. Stefansson and 
colleagues found a large inversion polymorphism on chromosome 
17q21.31 that was common among Europeans with an inversion frequency 
of 21% but rarer in Africans (6%) and even rarer among Asians (1%) 
(Stefansson et al., 2005). Analysis on H2 lineage of chromosome 17q21.31 
inversion showed that the carrier females of this inversion polymorphism 
have more children and higher recombination rates (Stefansson et al., 
2005). 
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1.1.3.1: Copy Number Variation (CNV) and its consequences 
DNA copy number variation (CNV) has long been known as a source of 
genetic variation, but its importance has only been appreciated recently 
from studies using new technologies (Iafrate et al., 2004; Sebat et al., 
2004; Redon et al., 2006). These studies have identified a previously 
uncharacterized prevalence of structural variants of DNA along 
chromosomes in the size range of 1kb or greater in the human genome, 
termed submicroscopic copy number variations. Copy number variation 
(CNV) is defined as change of DNA dosage of DNA segments greater than 
1 kb in size (and typically less than 3 Mb) (Scherer et al., 2007). CNV is 
characterized by variable numbers of copies of a DNA segment (Feuk et 
al., 2006), and large copy number variants tend to be flanked by segmental 
duplications. New copy number variation may arise from NAHR as 
discussed earlier but can arise even when there is no sequence similarity 
between flanking sequences, via simple non-homologous end-joining to 
repair double-stranded DNA breaks that can lead to loss or gain of 
nucleotides from imprecise repair.  
 
Iafrate et al. (2004) and Sebat et al. (2004) demonstrated a higher level of 
large scale copy number variants to be common among apparently 
phenotypically normal individuals than previously appreciated. Even 
though both of these research teams used technologies that are limited in 
coverage and resolution, the unexpected scale of CNV that was found 
promoted research interest and further high resolution analyses. Moreover, 
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Redon and colleagues found 1447 copy number variable regions spanning 
a total of 360 Mb of sequence, which comprises at least 12% of the human 
genome for a large panel of ethnically diverse individuals (Redon et al., 
2006). They studied 270 lymphoblastoid cell lines from the International 
HapMap project, established from individuals of African, European, and 
Asian origin.   
 
More recently, several studies have shown that some genes that appear 
variable in copy number can have important functional consequences. 
Given that, it seems likely that this variation may play a fundamental role in 
influencing human disease susceptibility. However, not all variations in 
genomic structure have an effect. Among the variations that do cause 
effects, some are more serious than others. The outcome depends on two 
factors: where in the genome the change occurs (for example, in a non-
coding region, coding, or regulatory region) and the exact nature of the 
change such as the size and boundaries of the changes. The AMY1 gene, 
which encodes salivary amylase was one of the large scale CNV identified 
and observed in half the individuals studied by Iafrate and co-workers with 
relative gains and losses in equal numbers of people (Iafrate et al., 2004). 
Further study by Perry and colleagues on this gene found that it varied in 
copy number from two to 15 with a mean of seven in the European-
American population (Perry et al., 2007).  The authors compared the CNV 
in AMY1A between different population groups sampled from Africa, Asia, 
and Europe, and found particular groups that consume high starch diets 
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did indeed have more AMY1A copies. They also proposed that there had 
been positive or directional selection for CNV among these individuals, 
while in populations with low starch diets, there had been genetic drift and 
the locus had evolved neutrally (Perry et al., 2007).  
 
Another example is the CYP2D6 gene found at chromosome 22q13.1. This 
copy number variable gene was first described with individual alleles 
between zero and thirteen copies (Johansson et al., 1993). CYP2D6 is 
involved in the metabolism of an estimated 20 ± 25% of all marketed 
drugs, and thus genetic polymorphism of CYP2D6 is responsible for much 
of the observed variation between individuals in enzyme activity (Ingelman-
Sundberg et al., 2007). For example, individuals who have more than two 
active functional copies of a CYP gene may demonstrate increased drug 
metabolism and absence of response at ordinary drug dosages (ultrarapid 
metabolzers) while poor metabolizers lack functional enzyme due to 
defective or deleted genes. Currently, there is an increasing amount of 
published work on the potential role of copy number variation in complex 
diseases including susceptibility to autism, schizophrenia, psoriasis, 
systemic lupus erythematosus (SLE) and HIV-1. For example, the genes 
CCL3L1, CCL4L1, and TBCID3 are present in different copy numbers 
(between 0 and 10 copies per individual) within and between populations. 
In Europe, common variation is from zero to four copies, whereas in Africa, 
copy numbers as high as ten have been recorded. This variation is 
reported to be involved in susceptibility to, and progression of, infection 
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with HIV-1 (Townson et al., 2002; Gonzalez et al., 2005). For individuals 
with a higher number of CCL3L1 copies, the risk was significantly reduced, 
while lower copy numbers were associated with faster disease 
progression.  
 
Beta-defensin genes, the genes of interest in this study, are located on 
chromosome band 8p23.1 and were found commonly to be variable 
between two to seven copies, but in some individuals there were up to 12 
copies present (Hollox et al., 2003). These genes encode small secreted 
antimicrobial peptides with cytokine-like properties as described in section 
1.2.2. Hollox and colleagues have highlighted the role of copy number 
variation on this region in susceptibility to psoriasis; when more than four 
copies in diploid genome were present, each extra copy increased the 
relative risk of disease (Hollox et al., 2008). Intriguingly, two different 
studies at this locus demonstrated different finding of association with 
LQIODPPDWRU\ ERZHO GLVHDVH SDUWLFXODUO\ LQ FRORQLF &URKQ¶V GLVHDVH
(Fellermann et al., 2006; Bentley et al., 2009), which will be discussed in 
chapter four. In contrast, individuals with lower numbers of copies of total 
the C4 and C4A genes were found with increasing risk of the autoimmune 
disease SLE, and higher copy numbers were a protective factor against 
SLE susceptibility in European Americans (Yang et al., 2007). Another 
example is FCGR3B gene which encodes the Fc fragment of IgG, low 
affinity IIIb receptor on chromosome band 1q23, which has copy number 
ranges from none, one, two, three and four diploid copies. Low copy 
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number of this gene is found significantly increased risk for 
glomerulonephritis disease (Aitman et al., 2006; Fanciulli et al., 2007).  
 
Copy number variation of DNA sequences may be functionally remarkable 
because it can influence or correlate with the level of gene expression 
through effects on gene dosage in which there is loss or gain of functional 
gene copies (McCarroll et al., 2006). It may also act indirectly through 
position effects, predisposition to deleterious genetic changes, or by 
providing substrates for chromosomal changes in evolution (Feuk et al., 
2006). A genome-wide analysis of the association between copy number 
variation and gene expression was undertaken using lymphoblastoid cell 
lines established from 210 unrelated individuals in the International 
HapMap Project from four populations (Stranger et al., 2007). The authors 
found a significant association between copy number variation and gene 
expression with as much as 17.7% of the heritable variance in gene 
expression attributable to copy number variation.  
 
For nearly all genes in the human genome commonly present as two 
copies, each copy has been inherited from each parental genome so that 
every diploid cell carries two copies of a gene in the nucleus. However 
when (for example) a copy number variable gene is measured as three 
copies per diploid genome, there are two possible haplotype combinations, 
corresponding to either 1 + 2 or 3 +0. Moreover, there is also no 
information of which of these haplotypes will be inherited from which parent 
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except by segregation analysis of copy number alleles in a pedigree. Copy 
number genotyping is not as simple as SNP or other basic deletion or 
duplication events as shown in the figure 2, adapted from Wain 
et.al.,(2009). The simplest copy number variation is the presence or 
absence of a gene as illustrated in figure 2A. For example in European 
population, the rhesus-negative allele at the main antigen locus for the 
rhesus blood group is commonly caused by complete deletion of the RHD 
gene and aQLQGLYLGXDO¶VGLSORLG genome could therefore contain two, one, 
or zero copies of RHD, with the zero copies corresponding to rhesus-
negative and absence of D antigen expression. Genomic segments with 
variable copy number could encompass parts of genes, reside entirely 
outside genes, or, in the case of larger variants, include several known 
genes. Thus, a simple duplication of a genomic segment could result in 
diploid copy numbers of two, three, or four (figure 2B), and successive 
rounds of duplication could produce a wide range of diploid copy numbers, 
known as multiallelic copy number variants (figure 2C) which involves more 
complex variation. All of this information is not been explored very well yet 
for many CNVs in the human genome. It may contribute important 
knowledge to the genotype-phenotype correlation for copy number 
variation. In order to address the lack of studies on the origin of the copy 
number in the locus-specific genes, the human defensin genes, particularly 
of the beta-defensin class located at chromosome 8p23.1, were chosen as 
the region to examine in this study. This region is one of the most 
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fascinating examples of structural variation in the human genome and is 
also associated with autoimmune disease. 
 
Figure 2: Diallelic and multiallelic copy number variation. Diallelic locus 
(grey) and flanking loci (green and blue) with variation caused by (A) 
deletion and (B) duplication, each showing the locus with (i) normal copy 
number, (ii) heterozygous modification, and (iii) homozygous modification. 
(C) Multiallelic locus showing (i) normal copy number, (ii) multiple rounds of 
duplication on one chromosome and a deletion on the homologous 
chromosome, (iii) duplication on one chromosome and no deletion on the 
homologous chromosome, (iv) two rounds of duplication on one 
chromosome and no deletion on the homologous chromosome, (v) one 
round of duplication on each chromosome, (vi) one round of duplication on 
one chromosome and two rounds of duplication on the homologous 
chromosome, and (vii) two rounds of duplication on both chromosomes. 
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Multiallelic assays measure diploid copy number and therefore cannot 
distinguish between (ii) and (iii), or (iv) and (v). Note that although 
duplications are usually assumed to be contiguous, this might not always 
be the case (figure was taken from Wain et al., (2009)). 
 
1.1.4: Human Chromosome 8p23.1  
Human chromosome 8p23.1 as shown in figure 3 is a good example to 
study several types of structural variation. This region is known to be a 
frequent site of chromosomal rearrangements mediated by two large 
blocks of low copy repeats (LCRs) or segmental duplications (SDs). The 
whole 8p23.1 region, which includes the SDs and contains at least 50 
genes, can extend up to 6.5 Mb. The two large set of SDs blocks are 
named REPeat Distal (REPD) distally and REPeat Proximal (REPP) 
proximally. Each of  the two SDs includes olfactory receptor gene clusters 
and other genes such as defensins and FAM90A clusters which are found 
to be copy number variable (Hollox et al., 2003; Aldred et al., 2005; Bosch 
et al., 2008). Thus, the sizes of the flanking SDs are variable with gaps that 
are not fully sequenced in the assembled genome sequence. These 
characteristics seem to be sufficient for this SD variability to play an 
important role in the distinct rearrangement affecting the 8p23.1 region 
(Bosch et al., 2009).    
 
Furthermore, Giglio et al. (2001) first reported inversion heterozygosity of 
the chromosome 8p23.1 region with 26% in the population of European 
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descent, and Sugawara et al. (2003) found 34% in Japanese populations. 
This is one of the most common submicroscopic inversions identified in 
autosomes assuming that the assembly of the reference sequence 
corresponds to the non-inverted conformation. Further studies have found 
an increased frequency of this inversion (around 60%) in populations of 
European ancestry that indicates the human reference assembly 
corresponds to the minor allelic orientation of this region (Chen et al., 
2006; Libin et al., 2008; Antonacci et al., 2009). The relevance of this 
inversion variant in the general population is its relationship with flanking 
segmental duplications (REPD and REPP), which may also be involved 
with generation of copy number variations (CNVs) during crossover. The 
type of rearrangements are predominantly defined by the orientation of 
recombining duplicons and the number of crossovers for example, deletion 
and reciprocal duplications result from mismatch of direct repeats and a 
single crossover between the distal and the proximal repeat. Inversions 
could result through mispairing of inverted repeats and a double 
recombination event between them (Small and Warren, 1998). 
 
Interestingly, the DEF cluster is assembled at this region, the defensin 
gene clusters including alpha, beta and theta-defensins. The beta-defensin 
clusters have been identified at REPD in 8p23.1. Both alpha and beta-
defensins have been found to be variable independently as described in 
sections 1.2.1 and 1.2.2. In the 1990s, cytogenetically visible alteration at 
this region was first reported but was apparently benign (Barber et al., 
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1998) and over the next decade, the vast majority of individuals carrying 
additional 8p23.1 material did not have any identifiable phenotypic 
abnormalities (Barber et al., 1998; Barber et al., 2005). 
 
Figure 3: Chromosome 8p23.1 region flanking with two large blocks of 
segmental duplication named as REPD distally and REPP proximally. The 
beta-defensin clusters appear twice here. Figure illustrated from the UCSC 
Genome Browser on Human March 2006 (NCBI36/hg18) Assembly. 
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1.2: Human defensins  
Defensins are among the most important antimicrobial peptides in the 
innate immune system in humans and other mammals. They have 
molecular masses of 3.5 ± 6 kDa and encode a family of small cationic 
antimicrobial peptides characterized by six conserved cysteine residues 
cross-linked through disulphide bridges. Based on the arrangement of the 
cysteines and the disuphide-bonding pattern, these peptides are divided 
into three subfamilies: alpha-defensins, beta-defensins, and theta-
defensins (Ganz, 1999; Yang et al., 2001). In humans most of the genes 
encoding alpha and beta-defensins are located in clusters on chromosome 
8p23.1 as illustrated in figure 3 but they appear as well in other clusters on 
chromosome 6 and 20 (Linzmeier et al., 1999; Taudien et al., 2004). The 
disulphide linkages of cysteine residues in alpha-defensins are between 
the first and the sixth cysteine residues Cys1-Cys6, Cys2-Cys4, and Cys3-
Cys5, whereas in beta-defensins, the linkage are Cys1-Cys5, Cys2-Cys4, 
Cys3-Cys6. In contrast, theta-defensins have a circular structure with the 
cysteine residues linked as Cys1-Cys6, Cys2-Cys5, Cys3-Cys4 (Tang et al., 
1999; Klotman and Chang, 2006). 
 
1.2.1: Alpha defensins  
Alpha-defensins, which have been identified in humans, monkeys and 
several rodent species, are particularly abundant in neutrophils, certain 
macrophage populations, and Paneth cells of the small intestine. Human 
alpha-defensins 1, 2, 3, and 4 (DEFA1 to DEFA4) are constitutively 
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produced by neutrophils, whereas DEFA5 and DEFA6 are produced in the 
Paneth cells. Most alpha defensin genes (DEFA6, DEFA4, DEFA1, 
DEFA3, and DEFA5) are found in a cluster at the telomeric end of band 
8p23.1 with DEFA1 and DEFA3 appearing as a 19 kb tandemly repeated 
unit. Gene nomenclature for DEFA1 and DEFA3 has been replaced by 
DEFA1A3, following the recommendation of Aldred et al. (2005). DEFA1 
and DEFA3 encode different peptides, human neutrophil-derived alpha-
defensin 1 (HNP-1) and human neutrophil-derived alpha-defensin 3 (HNP-
3) respectively. The mature HNP-1 and HNP-3 peptides differ only in their 
N-terminal amino acid, due to single nucleotide difference, C3400A (Ganz 
and Lehrer, 1995). C3400A is a paralogous sequence variant (PSV) that 
allows discrimination between the two gene copies. HNP1, HNP2, and 
HNP3 peptides are easily purified from leucocytes, and their properties has 
been widely studied while HNP4, HNP5 and HNP6 have been recovered 
only in small amounts; considerably less is known about their properties 
(Harwig et al., 1992).  
 
The HNP-2 peptide is identical to the last 29 amino acids of both the HNP-
1 and the HNP-3 peptides. Given that no gene for DEFA2 has been 
discovered, it is thought that DEFA2 is a proteolytic product of one or both 
of DEFA1 and DEFA3. Thus, HNP-2 is presumably produced from 
proHNP-1 and/or proHNP-3 by post-translational proteolytic cleavage 
(Ganz, 2003). HNP-1 peptide is likely to play a role in phagocyte-mediated 
host defense. These three peptides (HNP1, HNP2 and HNP3) are 
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constitutively produced by neutrophil cell precursors and packaged in 
granules before mature neutrophils are released into the blood. During 
phagocytosis, the defensin-containing granules fuse to phagocytic 
vacuoles where defensins act as antimicrobial agents (Ganz and Lehrer, 
1995). Human alpha-defensin 5 (HNP5) is released as a propeptide that is 
processed extracellularly (Ghosh et al., 2002). To date, alpha-defensins 
have been shown to have broad and very powerful anti-microbial activity, 
such as the anti HIV activity recently shown for DEFA1 (Cole et al., 2002).  
 
1.2.2: Beta defensins  
A beta-defensin was first reported as the tracheal antimicrobial peptide 
(TAP) of cow tongue (Diamond et al., 2000). A similar functional and 
structural property of this peptide to those described earlier for alpha-
defensin assigned TAP to the defensin family. In the beta-defensins, the 
three disulphide bridges are between residues 1 and 5, 2 and 4, and 3 and 
6 which is different from alpha-defensin (Cys1-Cys6, Cys2-Cys4, Cys3-
Cys5). In 1995, the first human beta-defensin, HBD-1 was isolated from the 
plasma of patients undergoing dialysis treatment for renal disease (Bensch 
et al., 1995). Bensch et al. (1995) found that HBD-1 is expressed in 
epithelial cells that are directly exposed to the environment or microbial 
flora, for example in the lung, mammary gland, salivary gland, kidney, 
pancreas, and prostate. HBD-1 has also been implicated in cancer as it is 
lost at high frequencies in malignant prostatic tissue and has been shown 
to induce cytolysis and apoptosis in prostate cancer cell lines (Sun et al., 
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2006). The second human beta-defensin, HBD-2, was originally 
characterized from psoriatic skin lesions and is widely expressed in 
epithelia (for example in respiratory tract, gastrointestinal tract, urogenital 
system, pancreas and skin), leucocytes and the bone marrow (Harder et 
al., 1997). Meanwhile, another defensin, HBD-3 was nearly simultaneously 
isolated from lesional psoriatic scales and cloned from keratinocytes and is 
a broad spectrum peptide antibiotic that kills many pathogenic bacteria 
(Harder et al., 2001).  
 
Their antimicrobial activity, predominantly against Gram-negative bacteria 
and sometimes against Gram-positive bacteria, varies such that, HBD-1 is 
active against Gram-negative bacteria and HBD-2 has considerably 
greater activity compared to HBD-1. Meanwhile HBD-3 has the strongest 
activity. HBD-2 and HBD-3 are also induced by inflammatory stimuli such 
as tumour necrosis factor alpha (TNF-Į). Consequently, three other beta-
defensin genes (HBD-4 ± 6) were discovered by using the Basic Local 
Alignment Search and HBD-4 was found to be highly expressed in the 
testis and epididymis (Yamaguchi et al., 2002). More recent work has 
demonstrated that their functional role seems not to be limited as classic 
antimicrobial peptides only and further functional study may cover 
unexpected different roles for what is increasingly regarded as a 
multifunctional gene family.  
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The main beta-defensin gene cluster is located within chromosomal band 
8p23.1 (figure 3) and is somewhat larger than the alpha-defensin cluster, 
spanning at least 250 kb in size of repeat unit. The exact size of the beta-
defensin repeat unit is unclear and may itself be variable, although from 
pulse-field gel analysis it is shown to be at least about 260 kb in size 
(Hollox et al., 2003). Subsequently, three other beta-defensin gene clusters 
were been identified within chromosomes 6 and 20 (Schutte et al., 2002; 
Rodriguez-Jimenez et al., 2003). A gene with strong homology to beta-
defensin genes called epididymis-specific secretory protein 
(EP2/HE2/SPAG11) is found to be encoded by a human gene within 
chromosome 8p23.1 near several other beta-defensin genes (Horsten et 
al., 2004). It is encodes an androgen-dependent molecule that is 
specifically expressed in the epithelium of the male reproductive tract. Most 
genomic structures of the beta-defensin genes contain two exons and one 
intron, with an exception for the DEFB105 gene, which contains three 
exons and two introns. The first exon generally encodes the signal peptide 
and the second carries information about the mature peptide sequence 
preceded by a short anionic pro-peptide; this is not true for DEFB1, for  
which the first exon encodes both the signal peptide and pro-peptide 
segment (Liu et al., 1997). HBD-2 has been demonstrated to be subject to 
gene copy number variation and polymorphic within the healthy population 
(Hollox et al., 2003). Copy number variation of the DEFB4 gene (HBD-2) 
has been thought to be associated in development RI FRORQLF &URKQ¶V
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disease (Fellermann et al., 2006; Bentley et al., 2009) and psoriasis 
(Hollox et al., 2008). 
 
1.2.3: Theta defensins 
The only primate theta-defensin described so far are isolated from rhesus 
macaque leucocytes: rhesus theta-defensin 1 (RTD1), RTD2 and RTD3 
(Tang et al., 1999). The mature theta-defensin peptides arise by an as-yet-
uncharacterized process that generates a cyclic peptide by splicing and 
cyclization from two of the nine amino acid segments of alpha-defensin-like 
precursor peptides (Ganz, 2003). The theta-defensins apparently evolved 
in primates, but are inactivated in humans due to premature stop codons in 
the genes that abort translation and subsequent peptide production (Cole 
et al., 2002)  
 
1.2.4:       Copy number variation in human defensin genes  
In 1995, CNV of DEFA1 had been observed from somatic cell hybrid 
mapping of chromosome 8 (Mars et al., 1995). Aldred et. al (2005) and 
Linzmeier et. al (2005) found that the Į-defensins DEFA1 and DEFA3 are 
variable in copy number. The other alpha-defensins (DEFA4, DEFA5 and 
DEFA6) and the beta-defensin DEFB1 do not show copy number variation 
(Hollox et al., 2003; Aldred et al., 2005; Linzmeier and Ganz, 2005). The 
8p23.1 beta-defensin cluster including the DEFB4, DEFB103, DEFB104, 
DEFB105, DEFB106, DEFB107 and SPAG11 genes, was found to be 
polymorphic in copy number. Most previous studies measured beta-
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defensin copy number at different sequences along the repeat region, and 
found all the above genes varied concordantly (Hollox et al., 2003; Groth et 
al., 2008; Abu Bakar et al., 2009). Furthermore, none of the studies have 
provided any support for extensive copy number heterogeneity, and all 
copy number typing methods for a given sample generally report the same 
copy number.  
 
In cytogenetic analyses, chromosomes carrying high-copy alleles are 
visible as 8p23.1 euchromatic variants in individuals found to have nine to 
twelve copies of the region, whereas most other normal people have two to 
seven copies per diploid genome (Barber et al., 1998; Hollox et al., 2003; 
Barber et al., 2005). One copy of the beta-defensin cluster per diploid 
genome has been observed in only one individual among more than 1500 
individuals typed using DNA from blood (Hollox et al., 2008). The author 
and colleagues suggested that the null state exists but is very rare with 
haplotype frequency as low as 0.2%. Additionally, the beta-defensin 
clusters on chromosome 20 do not show common CNV (Hollox and 
Armour, 2008).  
 
1.3: Methods for detection and measurement of  
genome variation 
At present there are several assays that have been used for the detection 
of human genetic variation, ranging from point mutations to the larger 
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genomic variation over more than 100bp. Nevertheless, every single assay 
has limitations in both quantitative and qualitative terms. Development of 
all of the techniques depends on the type of variation and the features of 
the methods. Early studies led to the concept of genomic variation from 
detection of disorders in individuals, and chromosome analysis is a method 
to visualize the entire human genome.   
 
1.3.1: Chromosomal aberrations 
Chromosomal aberrations include changes in the normal number of 
chromosomes per individual (46 chromosomes per diploid cell) either to 
fewer chromosomes (45 chromosomes) or more, such as 47 
chromosomes. Conventional cytogenetic analysis including staining of the 
chromosome bands is more useful for this detection and G ± banding is 
one of the most common methods of chromosome banding (Yunis and 
Sanchez, 1973; Speicher and Carter, 2005). This technique has been 
broadly used in the clinical laboratory for both pre- and postnatal diagnosis, 
and in oncology, where karyotyping allowed scientists to look for somatic 
chromosomal alterations. However, this technique will not always allow 
scientists to detect other structural abnormalities such as small-scale 
duplication or translocation. Due to those limitations, molecular 
cytogenetics has been developed from the 1980s. Hybridizing fluorescently 
labelled probes to chromosome preparations, fluorescent in situ 
hybridization (FISH) has allowed investigators further advances in 
examination of chromosome structure as discussed in the next section. 
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Comparative genomic hybridization (CGH) (Kallioniemi et al., 1992) and 
spectral karyotyping (SKY) (Schrock et al., 1996) were then developed to 
screen the whole set of chromosomes per individual. All of the above 
techniques from a cytogenetic viewpoint are able to identify structural 
variation qualitatively, and are useful for detection of some structural 
variation in the whole genome. Moreover, structurally abnormal variants 
including translocations, inversions, deletions and duplications are less 
frequently identified than aneuploidies at the karyotype level.  
 
1.3.2: Structural variation including copy number variation (gene  
dosage) 
Most of the techniques used to investigate structural variation in the human 
genome may divided into two groups; polymerase chain reaction based 
(PCR-based) and array-based comparative genomic hybridisation (CGH), 
with the exceptional of the cytogenetic methods as discussed above and 
Southern blot hybridisation. There are huge numbers of PCR-based 
techniques widely used as experimental tools for genetic analysis, 
combining a highly specific primer hybridization process with exponential 
amplification of the target sequence. Modifications of PCR to a quantitative 
process suitable for the measurement of gene dosage have been carried 
out by considering a number of factors in the theory and principle of the 
PCR technique. In analysis of copy number polymorphisms, PCR can be 
used to amplify abundant DNA polymorphic markers like microsatellites 
and SNPs which has allowed investigators to obtain gene dosage 
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information in some instances, for example in the detection of large 
deletions and duplications within chromosome 17p11.2 in Charcot-Marie-
Tooth disease type 1A (Brice et al., 1992). However, the preferential 
amplification of the smaller allele, and the stuttering effect that produces a 
series of minor peaks immediately adjacent to the major peak, has made 
microsatellite analysis more difficult to interpret. Nevertheless, the 
difficulties with quantitative fluorescent PCR (QF-PCR) of microsatellites 
are reduced by the use of tetranucleotide repeat markers, and multiplex 
QF-PCR is finding increasing use in the rapid diagnosis of the common 
aneuploidies (Armour et al., 2002). SNPs which are less informative 
individually than microsatellites but far more abundant can be used for high 
throughput genotyping. A number of PCR-based techniques have been 
developed such as competitive PCR, differential PCR, Real-Time PCR, 
Long PCR, MAPH, MLPA, and PRT. Some of them are described in the 
following paragraph on detection and measurement of the structural 
variation, including copy number variants in the human genome. 
Meanwhile, developments of array-based CGH have encouraged its use in 
detection and mapping structural variations.  
       
Previous studies have identified human genomic variation among 
unrelated individuals by using different approaches. The most commonly 
used method to detect CNV was array comparative genomic hybridization 
(aCGH) developed by Pinkel and colleagues. They demonstrated the 
ability of aCGH to measure copy number with high precision in the human 
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genome, and to analyse clinical specimens by obtaining new information 
on chromosome 20 aberrations in breast cancer (Pinkel et al., 1998). The 
method uses an array of probes that represent the genome and 
differentially labelled test and reference DNA samples that are jointly 
hybridized to the array; at each probe, the ratio of the labels is used to 
identify comparative deletions or duplications of the DNA. An array could 
be of either bacterial artificial chromosome (BAC) clones, in which 
fragments of genomic DNA (80-200 kb) from across the genome can be 
inserted into the bacterial plasmid and replicated, or synthetic 
oligonucleotides, which are often uses as targets. Iafrate et al. (2004) also 
using BAC clone array CGH described large-scale copy number variations 
(LCVs), involving gains and losses of several kilobases to hundreds of 
kilobases of genomic DNA; they found twenty-four variants in more than 
ten percent of the 55 unrelated individuals by using similar methods 
(Iafrate et al., 2004).  
 
Sebat et al. (2004) showed that large-scale copy number polymorphisms 
(CNPs) (at a scale of about 100 kilobases and greater) contribute 
substantially to genomic variation between normal human genomes by 
using representational oligonucleotide microarray analysis (ROMA) of 20 
individuals. The study revealed a total of 221 copy number differences 
representing 76 unique copy number polymorphisms (CNPs). This method 
is a variant of array-CGH in which the reference and test DNA samples are 
made into ³representations´ to reduce the sample complexity before 
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hybridization to a custom oligonucleotide array (Sebat et al., 2004). 
However, the most common variant in the Iafrate et al.,(2004) study, 
located at 1p21.1 (AMY1A-AMY2A) and present in >49% of the individuals 
studied, was not detected by Sebat et al. (2004). Therefore, this might 
suggest that the coverage or resolution of the methods used is different 
between those two studies. Furthermore, data from array comparative 
genomic hybridization are often much harder to assess than a sequence 
trace and sometimes may overestimate the size of the copy number 
variant because signal ratio from BAC clones is mapped onto the extent of 
the fragment of DNA inserted into the bacterial plasmid.  
 
By contrast, CNV sequencing-based approaches can map copy number 
variants with much greater accuracy than aCGH, and can detect inversions 
or translocations (Wain et al., 2009). Currently there are two possible ways 
of comparison of a segment of reference and test DNA sequences which 
are paired-end mapping (PEM) (Korbel et al., 2007) and fosmid end 
sequencing (Tuzun et al., 2005; Kidd et al., 2008). For fosmid cloning, 
genomic DNA is inserted into a fosmid cloning vector and transfected into 
cells for propagation. Only a restricted size range of DNA inserts (32 ± 48 
kb) can be efficiently cloned (Tuzun et al., 2005) whereas PEM directly 
uses a test sample prepared from size-selected genomic DNA (Korbel et 
al., 2007). In addition Tuzun and colleagues published the results of a 
sequence-based approach to try to produce a fine scale map of structural 
variation across the genome (Tuzun et al., 2005). They found 297 sites of 
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variation including 139 insertions, 102 deletions, and 56 inversion 
breakpoints; 28% showed copy number variation when 57 sites were 
analysed and validated by array CGH. They also noted overrepresentation 
of structural variation for genes involved in drug detoxification, innate 
immunity and inflammation, surface integrity, and antigens (Tuzun et al., 
2005). These recent studies have shown that sequencing-based 
approaches have played an important part in development of maps of copy 
number variation, but at present, the expense of this technique prohibits 
their application on a genome-wide scale across many individuals.  
 
Another method for mapping CNV is using signals from SNP arrays as a 
proxy, though early SNPs arrays sometimes excluded many SNPs from 
regions of copy number variants. New hybrid oligonucleotide microarrays 
may overcome this limitation, which include non-polymorphic probes to 
detect copy number variation (widely referred to as non-SNP probes or 
copy number variant probes) and probes for many more SNPs that were 
excluded in the early arrays. These arrays have been developed to 
accurately analyze SNPs and copy number variation simultaneously 
(McCarroll et al., 2008). Mccarroll et al., used these arrays to map the 
genomic locations, allele frequencies and population-genetic properties of 
human copy number polymorphisms (CNPs); and to apply this knowledge 
to advance strategies for querying CNV in genome-wide association. 
Interestingly, McCarroll and co workers documented that large-scale (>100 
kb) CNV affects far less of the human genome than previously reported. 
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However, this approach also has its own limitation; it is limited to 
sequences that are already present in the finished human genome 
sequence, and it misses many regions of high multiplicity duplication 
(McCarroll et al., 2008).   
 
Instead of just detection and mapping of the CNV, there are other methods 
that have been developed for measuring the real changes of copy number 
variants. Multiplex amplifiable probe hybridization (MAPH), combines 
hybridization as the primary step to detect copy number with PCR to 
amplify the hybridized probes (Armour et al., 2000). However, the MAPH 
method requires labour-intensive preparation of probe sets for each assay 
but is ideally suited to apply to large numbers of samples, which require 
testing at a medium number of segments, such as the 23 exons of BRCA1. 
A similar method, by sharing some of the features of MAPH, is the 
multiplex ligation-dependent probe analysis (MLPA) developed in 2002 to 
quantify 40 different DNA sequences using only 20ng of human DNA 
(Schouten et al., 2002).  
 
Another established method is real time quantitative PCR (RT-qPCR) 
which works well for scoring individual deletions and duplications, but is not 
generally suitable for multiplexing (Barrois et al., 2004; Feuk et al., 2006). 
FISH can be used as confirmation of the larger structural variants found by 
some array-based experiments (Feuk et al., 2006). Microsatellite analyses 
are likely to show multiple lengths of alleles, up to a maximum of the 
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number of copies of CNV. This technique is possible as a good support for 
other methods in measuring copy number variants by determining the 
allele ratios as a measure of possible integer copy number (Hollox et al., 
2005; Abu Bakar et al., 2009). 
 
Armour et al. (2007) demonstrated the Paralogue Ratio Test (PRT) as an 
assay that requires as little as 10ng genomic DNA which appears to be 
comparable in accuracy to the other methods in determination of copy 
number variation (Armour et al., 2007). This assay has been suggested as 
the first one that can provide a rapid, simple, and inexpensive method for 
copy number analysis suitable for application to typing thousands of 
samples in large case-control association studies. Different studies have 
used this PRT assay for typing beta-defensin copy number variation 
(Armour et al., 2007; Abu Bakar et al., 2009). Walker et al. (2009) have 
developed a multiplex paralogue ratio test (PRT) that included three PRT 
systems, which can be used in combination to measure copy number at 
the CCL3L1 locus.  
 
1.3.3: Methods for typing defensin copy number  
Recently, there are several methods used in determination of defensin 
copy number, yet there is still a lack of studies on this single-locus copy 
number variable region, perhaps due to the complicated structure of the 
territory. Detection of defensin copy number was first begun with the typing 
of beta-defensin copy variants using MAPH with several probes across the 
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beta-defensin region (Hollox et al., 2003), in which the investigators also 
used microsatellite dosage and semi-quantitative FISH analysis to further 
clarify the beta-defensin copy number. They also found one of the MAPH 
probes DEFA1.2, to be of variable copy number independently of the beta-
defensin cluster. Restriction enzyme digest variant ratios (REVDR), which 
involved amplification across a nucleotide variant or small deletion that 
differs between repeats, and determination of nucleotide ratio after 
restriction enzyme digestion of the amplification product and quantification 
of the resulting electrophoresis peaks, has also been used in order to 
determine the copy number of defensins (Aldred et al., 2005). 
 
The MAPH assay was utilized to investigate the relationship between beta-
defensin gene copy number and susceptibility to psoriasis, and the higher-
throughput paralogue ratio test (PRT) (Armour et al., 2007) was developed 
as an alternative assay for typing DEFB4 copy number (Hollox et al., 
2008). Hollox and colleagues declared that combining information from 
MAPH, PRT and ratios of multisite variants (MSVs) improved the overall 
accuracy of copy number determination in this study. Recently, comparison 
of multiplex ligation-dependent probe amplification (MLPA) which shares 
some of the features of MAPH ,and real-time PCR was carried out on beta-
defensin gene copy numbers quantification, with a pyrosequencing-based 
paralog ratio test (PPRT) used as the standard of that comparison (Perne 
et al., 2009). The authors claimed that the consistency of copy number 
given between MLPA and PPRT is higher than either real-time PCR/MLPA 
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or real-time PCR/PPRT based on the confirmed concordance of identical 
results in the samples. Real-time PCR has also recently been used in two 
different studies to examine the beta-defensin copy number and 
DVVRFLDWLRQ ZLWK &URKQ¶V GLVHDVH ZKLFK FDPH RXW ZLWK GLIIHUHQW
conclusions as described earlier (Fellermann et al., 2006; Bentley et al., 
2009).  
 
Complementary methods such as microsatellite analyses have been used 
to aid in clarifying beta-defensin copy number, and for tracking individual 
copies of a repeat through a pedigree; each repeat has a high chance of 
carrying a different length of allele (Hollox et al., 2003). Three STRs have 
been used in the first part of this study to distinguish ambiguous copy 
number diplotypes, to deduce the haploid copy numbers and to infer the 
individual haplotypes based on the allele segregation (Hollox et al., 2005). 
Short insertion-deletion (indel) analysis can also act like STRs in 
verification of the diploid and haploid copy number, as well as allele 
segregation, in which the different length of alleles can be amplified and 
resolved by using electrophoresis. Development of an accurate technique 
for typing copy number variation in a complex polymorphic region is a 
fundamental key for the initial understanding of the phenotypic 
consequences. 
 
Reliable detection of disease association of CNVs is limited by many 
factors as mentioned earlier including location, size and the breakpoints of 
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the changes (Wain et al., 2009). Wain and colleagues have reviewed the 
public database of these variants considering that the above factors have 
been very imprecise. There is improvement for the mapping from newer 
studies but still scalable methods to characterise copy number variation in 
association studies have been inexact. Moreover, potential for 
misclassification in copy number variation still remains much higher 
compared to SNPs. 
 
1.4:  Aims of the study 
This study is divided into two parts; the first is examination of the origin of 
the human beta-defensin diversity, and the second is developing a 
powerful and accurate assay to investigate the association of human beta-
defensin copy number variation in large case-control studies. The main 
goal of the first work which is elaborated in the chapter three is to measure 
and understand beta-defensin copy numbers variants in individuals by 
using the paralogue ratio test (PRT), a high throughput assay for typing of 
copy number variation. Subsequently, the specific and immediate 
objectives applied in this part are to investigate the detailed nature of 
variation in beta-defensins following the segregation of beta-defensin copy 
numbers in family pedigrees, and to examine the segregation patterns for 
evidence of any recombination events that occur between haplotypes, and 
any changes in copy number of beta-defensin in transmission from parent 
to children.  
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Developing a multiplex assay involving PRT as a powerful system for beta-
defensin copy number measurement is one of the major aims for the 
second work in this study and has been explained in chapter four. This 
new system is then applied to accurately determine the beta-defensin copy 
number in large case-control association studies to demonstrate the 















Chapter 2:  Materials and Methods 
 
2.1: Materials 
2.1.1: DNA samples used 
2.1.1.1: ECACC Human Random Control (HRC) samples 
ECACC Human Random Control (HRC) panels 1 and 2 
(http://www.hpacultures.org.uk/products/dna/hrcdna/hrcdna.jsp) were used 
in all studies for unrelated UK Caucasian control samples. The DNA 
samples were extracted from lymphoblastoid cell lines derived by Epstein 
Barr Virus (EBV) transformation of peripheral blood lymphocytes from 
single donor blood samples. The genomic DNA was provided as a solution 




2.1.1.2: CEPH samples 
From the Centre de'Etude du Polymorphisme Humain (CEPH) panel 
(http://ccr.coriell.org/Sections/Collections/NIGMS/CEPHResources.aspx?P
gId=525&coll=GM), a set of 26 multigenerational reference families with a 
total of 324 members was used in most studies as European test samples. 
The DNA samples were obtained from different populations as shown in 
table 1.  
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Table 1:  The list of CEPH families and numbers in each family included in 
this study. The CEPH families used in this study were derived from four 
different European populations; French, Venezuela, Old Order Amish and 







CEPH/FRENCH pedigree 2 9 
CEPH/FRENCH pedigree 12 13 
CEPH/FRENCH pedigree 23 8 
CEPH/FRENCH pedigree 35 10 
CEPH/FRENCH pedigree 37 6 
CEPH/FRENCH pedigree 45 10 
CEPH/FRENCH pedigree 66 11 
CEPH/VENEZUELA pedigree 102 16 
CEPH/VENEZUELA pedigree 104 14 
CEPH/OLD ORDER AMISH pedigree 884 18 
CEPH/UTAH pedigree 1331 17 
CEPH/UTAH pedigree 1332 16 
CEPH/UTAH pedigree 1333 14 
CEPH/UTAH pedigree 1334 13 
CEPH/UTAH pedigree 1341 10 
CEPH/UTAH pedigree 1345 13 
CEPH/UTAH pedigree 1346 14 
CEPH/UTAH pedigree 1350 13 
CEPH/UTAH pedigree 1362 17 
CEPH/UTAH pedigree 1375 12 
CEPH/UTAH pedigree 1408 14 
CEPH/UTAH pedigree 1416 16 
CEPH/UTAH pedigree 1421 6 
CEPH/UTAH pedigree 1424 14 
CEPH/UTAH pedigree 13292 12 
CEPH/UTAH pedigree 13294 8 
 
2.1.1.3: Disease cohort samples 
Three different disease cohorts were used to illustrate the application of 
the triplex system in association studies of copy number variation of -
defensin with common disease. The DNA samples were kindly supplied by 
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WKH IROORZLQJFROODERUDWRUV WZRGLIIHUHQWVHWVRI&URKQ¶V disease samples 
IURP &KULVWRSKHU 0DWKHZ .LQJ¶V &ROOHJH /RQGRQ DQd Jack Satsangi 
(University of Edinburgh) and a set of Rheumatoid Arthritis samples from 
Jane Worthington (University of Manchester) 
 
2.1.2: General reagents 
2.1.2.1: 10X PCR Mix 
10X PCR mix contained final concentrations of 50mM Tris-HCl (pH8.8), 
12mM ammonium sulphate, 5mM magnesium chloride (MgCl2), 125µg/ml 
BSA, 7.4mM 2-mercaptoethanol and 1.1mM of each dNTP. This buffer was 
used for some studies that required higher concentration of MgCl2 and 
dNTPs. 
 
2.1.2.2: 10X LD PCR Mix 
; /' ³/RZ G173´ PCR mix was another buffer containing final 
concentrations of 50mM Tris-HCl (pH8.8), 12.5mM ammonium sulphate, 
1.4mM magnesium chloride, 125µg/ml BSA, 7.5mM 2-mercaptoethanol 
and 200µM of each dNTP. 
 
2.1.3: Primer design 
All PCR primers were designed using the reference sequences for the 
region of interest from the UCSC Genome Brower March 2006 assembly 
(http://genome.ucsc.edu/). Primer3 software (http://frodo.wi.mit.edu/ ) was 
used to check thermodynamic properties of all the primers. Then, BLAST 
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(http://blast.ncbi.nlm.nih.gov) was used to search the Human DNA 
sequence Trace Archive for the sequence of many primers to ensure that 
primer pairs were unique to the sequence to be amplified and that no 
common sequence variants were observed.      
 
2.2: Standard Methods 
2.2.1:  Polymerase Chain Reaction (PCR) 
2.2.1.1: General / ABgene PCR 
PCR using ABGene buffer IV was used in some studies. Usually, 20µl 
PCR reactions were made as a master mix with the final concentrations of 
1X ABgene buffer IV, 1mM magnesium chloride (MgCl2) and 0.2mM each 
dNTP, 0.5µM each primer,  0.05U Taq DNA polymerase and 10ng input 
DNA. Products were then usually amplified using 35-37 cycles of 9Û&IRU
30 seconds, 60 C for 30 seconds and 70 C for 30 seconds. Exact cycle 
temperatures and times depended on the primers and the expected 
product. 
 
 2.2.1.2: PCR in 10X LD PCR or 10X PCR mix 
PCR in 10X PCR or 10X LD PCR buffer were commonly used in this study 
using 10µl or 20µl PCR reactions. The PCR reaction was made as a 
master mix with 10X PCR or 10X LD PCR buffer as described in sections 
2.1.2.1 and 2.1.2.2 with the final concentration as shown above in section 
2.2.1.1. However, PCR in 10X LD PCR mix was used in most studies. 
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ProGXFWV ZHUH WKHQ DPSOLILHG XVLQJ  F\FOHV RI Û& IRU  VHFRQGV
annealing for 30 seconds and 70 C for 30 seconds, followed by a single 
³FKDVH´ SKDVH RI DQQHDOLQJ IRU  PLQXWH C for 20 minutes to reduce 
levels of single-stranded DNA and complete terminDO ¶ G$ DGGLWLRQ
Precise cycle temperatures and times depended on the primers and the 
expected product. 
 
2.2.1.3: Nested PCR 
Nested PCR was used in the DEFB4 sequencing strategy to reamplify 
specifically only the region of interest. A standard method as described in 
section 2.2.1.2 was used in this PCR. However, as a secondary PCR, 
products were then amplified only using 20 - 25 F\FOHV RI Û& IRU 
seconds, annealing for 30 seconds and 70 C for 30 seconds.  
 
2.2.2: Sequencing 
Generally, two sequencing reactions per DNA product were set up; one 
with each of the two primers, using 200 l thin-walled tubes. The reaction 
mix per tube contained purified template, a final concentration of 1 M 
primer, 1X sequencing buffer (50mM Tris-HCl (pH 9.0) and 2mM MgCl2), 
the standard BigDye® Terminator (Applied Biosystem, UK) that contained 
four standard deoxynucleotides (dNTPs) and the four dideoxynucleotides 
(ddNTPs) each labelled with a different fluorescent dye, in a total volume of 
10 l. Products were usually amplified using 25 cycles of 96Û& IRU 
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seconds, followHG E\ Û& DQQHDOLQJ for 15 seconds and extension at 
60 C for 4 minutes. As with PCR cycles, precise cycle temperatures and 
times also depended on the primers and the expected product. 
 
2.2.3:  DNA Electrophoresis 
2.2.3.1: Agarose gel electrophoresis 
To measure the yield and size of PCR products amplified, DNA was 
separated by non-denaturing agarose gel electrophoresis. Agarose was 
dissolved by boiling in an appropriate amount of 0.5X TBE containing 
0.5 g/ml ethidium bromide to give a gel in the range of 0.7-2% (w/v). DNA 
samples to be run were prepared in a 10% solution of 10X loading buffer 
(0.025% bromophenol blue dye, 40% sucrose, 2.5x TBE buffer) and then 
loaded into the wells. Samples were run at 120V for 1 to 2 hours; bands 
were visualized by illumination under UV light and a photograph of the gel 
was kept for records. 
 
2.2.3.2: Capillary electrophoresis 
Capillary electrophoresis was carried out in this study using an ABI Genetic 
Analyzer 3100 instrumentation, (Applied Biosystems, UK). GeneScan 
analysis was performed using fluorescently labelled DNA. 1 to 2 l of PCR 
products were mixed with 10 l HiDi formamide, and 2 l of the internal size 
standard (GeneScan-ROX500, Applied Biosystems, UK) was included for 
precise determination of the length of the amplicons. After denaturation for 
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3 min at 96°C, the products were separated on POP-4 polymer (Applied 
Biosystem, UK) and analysed by 3100 GeneScan 3.1 software (Applied 
Biosystems, UK). Scanning results of fluorescent-dye-labelled PCR 
products (peak area) by GeneScan software were collected and 
transferred to an Excel spreadsheet file through Genotyper software 
(Applied Biosystems, UK) for further analysis.  
 
2.3: Paralogue ratio test (PRT) 
In order to measure the copy numbers of -defensin per diploid genome, 
three different systems of PRT assay were designed in this study with 
some modification from the one previously described by (Armour et al., 
2007). Table 4 below shows the list of primers designed to amplify from 
different locations inside the -defensin region.  
 
Table 2: PCR primer sequences from three systems of PRT assay used to 






HSPD5.8 was the first system for PRT assay used in this study to measure 
the copy numbers of DEFB4 (Armour et al., 2007). A pair of primers for 
HSPD5.8 as shown in table 2 was designed to amplify simultaneously the 
copy of a heat-shock protein pseudogene near DEFB4 on chromosome 8, 
and one other copy on chromosome 5. Products were amplified using PCR 
in 10X LD PCR mix as described in section 2.2.1.2 with 30 cycles of 95 C 
for 30 seconds, 53 C for 30 seconds and 70 C for 30 seconds, followed by 
a single ³FKDVH´SKDVHRI C for 1 minute/70 C for 20 minutes to reduce 
levels of single-VWUDQGHG '1$ DQG WR DOORZ WHUPLQDO ¶ G$ DGGLWLRQ WR
proceed to completion. Two parallel amplifications were carried out for 
each sample, one with a FAM label, the other with HEX. However, the 
(test) chromosome 8 (DEFB4) and (reference) chromosome 5 copies give 
PCR products too close in size (443 and 447bp respectively) to separate 
reliably by capillary electrophoresis. Therefore, digestion with restriction 
enzyme HaeIII to give products of 302 and 315bp was carried out so that 
the two products could easily be distinguished and quantified. Therefore, 
1µl of each PCR product was added, without further purification, to a 10µl 
digestion containing 1x ReAct 2 buffer (Invitrogen) and 5U HaeIII. After 
LQFXEDWLRQDWÛ&IRU-16 hours, 2µl were added to 10µl HiDi formamide 
with R-500 marker (Applied Biosystems), and analysed by capillary 




PRT107A was the second system of PRT assay developed to aid in 
clarification of DEFB4 copy numbers from HSPD5.8. PRT107A primers 
were designed to amplify simultaneously a dispersed repeat copy near 
DEFB107 on chromosome 8, and one other copy on chromosome 11. 
Although the PCR product formed by (test) chromosome 8 (DEFB107) and 
(reference) chromosome 11 copies were close in size, only differing by 2bp 
(157 and 155bp respectively), it was possible enough to separate them 
reliably by capillary electrophoresis. Products were amplified using PCR 
with 10X LD PCR mix as described in section 2.2.1.2 with pre-denaturation 
RIÛ&IRUPLQXWHVIROORZHGE\F\FOHVRIÛ&IRUVHFRQGV C 
for 30 seconds and 70 &IRUPLQXWHIROORZHGE\DVLQJOH³FKDVH´SKDVH
of 58 C for 1 minute and 70 C for 40 minutes. As for HSPD5.8, two parallel 
amplifications were carried out for each sample, one with a FAM label, the 
other with HEX; without any further digestion 1µl from each reaction was 
added to 10µl HiDi formamide with R-500 marker (Applied Biosystems), 
and analysed by capillary electrophoresis as described in section 2.2.3.2. 
 
2.3.3: HSPD21 
HSPD21, the third system of PRT assay, was also developed to aid in 
clarification of DEFB4 copy numbers. HSPD21 primers were designed to 
amplify simultaneously the copy about 3kb upstream of DEFB4 on 
chromosome 8 and one other copy on chromosome 21. In this study, 
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HSPD21 was carried out only in the development of triplex system as 
explained in 2.9. As with the other PRT systems, peak areas 
corresponding to the 172bp from near DEFB4 and the 180bp from 
chromosome 21 were recorded for both FAM- and HEX/NED- labelled 
products using GeneScan and Genotyper software (Applied Biosystems).  
 
2.3.4: Data analysis 
For HSPD5.8, peak areas corresponding to the 302bp HaeIII fragment 
from near DEFB4 and the 315bp fragment from chromosome 5, peak 
areas corresponding to the 157bp from near DEFB107 and the 155bp from 
chromosome 11 for PRT107A and peak areas corresponding to the 172bp 
from near DEFB4 and the 180bp from chromosome 21 in HSPD21 were 
recorded using GeneScan and Genotyper software (Applied Biosystems). 
The ratio 302bp/315bp, 157bp/155bp or 172bp/180bp for HSPD5.8, 
PRT107A and HSPD21 respectively were compared between FAM- and 
HEX- or NED- labelled products, and in most studies results were 
accepted if the difference between the ratios was less than 15% of their 
mean; this criterion led to the rejection of about 10% of tests. If accepted, 
the mean of the FAM and HEX or FAM and NED ratios was used in further 
analysis. Mean ratios were used in conjunction with reference samples of 
known copy number to calibrate each experiment, and the resulting (least-
squares) linear regression used to infer the copy numbers for unknown 
samples. Selected DNA samples giving reproducible results from several 
PRT assays were used as calibration standards (Figure 4a, 4b and 4c).  
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Figure 4: An example of the calibration standard on selected reference 
DNA samples, which give reproducible results from the PRT systems. The 
linear regression shown above has been used to infer the copy numbers 
for unknown samples. Figure 4a) was the reference DNA standard 
calibration for HSPD5.8, figure 4b) was the reference DNA standard 
calibration for HSPD21 and figure 4c) was the reference DNA standard 
calibration for PRT107A.   
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2.4: Microsatellite analysis 
Whenever the PRT assays indicated the copy numbers of -defensin in 
diploid genomes from CEPH family members, the segregation of variable 
copy number haplotypes from parents to children could be inferred by 
comparison with genotype data from other local markers drawn from the 
well-established CEPH genotype database 
(http://www.cephb.fr/en/index.php). Instead of just using PRT copy number 
measurement methods, three microsatellite analyses were chosen to 
clarify the segregation of the copy numbers of -defensin for haplotype 
analysis, and all of the primers are shown in table 3. To genotype 
microsatellites EPEV1, EPEV2 and EPEV3 in the DEFB4 region, 10ng of 
genomic DNA was amplified separately with three pairs of primers as 
shown in table 5 using PCR in 10X LD PCR mix as described in section 
2.2.1.2. PCR amplification used different annealing temperatures, 58 C for 
EPEV1, 60 C for EPEV2 and 56 &IRU(3(9RYHUF\FOHVRIÛ&IRU
minute, annealing temperature for 1 minute and 72 C for 1 minute, and 
final extension incubation of 72 & IRU  PLQXWHV WR FRPSOHWH ¶ G$
addition. After that, 1.5µl were added to 10µl HiDi formamide with R-500 
marker (Applied Biosystems), and analysed by capillary electrophoresis as 
described in section 2.2.3.2. Since labelled forward primers of EPEV1 and 
EPEV3 used the same fluorescent dye but produced different size ranges 
of alleles, both could be resolved in the same electrophoresis. For EPEV2, 
consideration of severe slippage as explained below meant that it was only 
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carried out on some of the CEPH families that needed further investigation 
and clarification of the recombination status.  
 
Table 3: PCR primer sequences from three microsatellites assays used to 
amplify different locations in the beta-defensin repeat 
 
 
2.4.1: Data analysis 
The most commonly encountered problems during microsatellite analysis 
are poor or non-VSHFLILFDPSOLILFDWLRQLQFRPSOHWH¶-dA nucleotide addition 
DQG DPELJXLW\ FDXVHG E\ WKH ³VWXWWHU´ SKHQRPHQRQ FDXVHG E\ 3&5
slippage. Although in this experiment, PCR amplification produced very 
VSHFLILFDPSOLILFDWLRQLQWKHH[SHFWHGVL]HUDQJHDQGDOPRVWFRPSOHWH¶-dA 
nucleotide addition, very careful attention was given to the stutter peaks 
caused by polymerase slippage during elongation. The stutter peaks that 
might occur during the PCR amplication of di-, tri- and tetranucleotide 
microsatellite loci appeared as minor products that are 1-10 repeat units 
shorter than the main allele product. In microsatellite analysis of EPEV1, 
EPEV2 and EPEV3 in the DEFB4 region, successful PCR amplification 
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produced a stutter peak just smaller than the main allele and was generally 
about 10-20% of the main allele peak area. After slippage patterns were 
recognized in each of the EPEV1, EPEV2 and EPEV3 analyses, assuming 
that slippage affects all alleles to the same degree then the effect of 
slippage in two adjacent alleles could be accounted for by quadratic 
equations for 3 peaks: x = a+1/2(b-¥Eð-DF \   FE¥Eð-4ac)) 
where a, b and c are the observed peak areas, and x and y the 
corresponding original peak areas (without slippage), as shown in figure 5. 
Simulations are used to reconstruct the original peak areas where there 




a stutter peak. The quantities x and y are the inferred true peak areas 
attributable to the two alleles.  
 
For example in EPEV1 (Figure 6), peak areas in the range 180bp and 
190bp were recorded using GeneScan and Genotyper software (Applied 
Biosystems). The major slippage peaks were always seen 2bp (i.e. one 
repeat unit; 178bp and 184bp in figure 6) shorter than the main allele 
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peaks, as expected for this dinucleotide repeat. Second-order slippage 
products were neglected in this analysis. Meanwhile for EPEV3 (figure 6), 
there were 3 main peaks; 136bp, 140bp and 142bp were recorded and 




Figure 6: An example of the GeneScan electropherogram showing EPEV1 
and EPEV3 resolved in the same electrophoresis. This sample had five 
copies of DEFB4 from the PRT assay, and five primary microsatellite 
alleles are visible at EPEV1 (180bp, 182bp, 186bp, 188bp and 190bp) and 
there are three primary peaks at EPEV3 (136bp, 140bp and 142bp), two of 
which correspond to two copies each (140bp and 142bp). 
 
2.5: Indel ratio measurements 
For further clarification of the copy numbers of -defensin in diploid 
genomes indicated by PRT assays, an insertion deletion (indel) ratio 
measurement assay was developed in this study. This assay also helped 
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the unambiguous inference of segregation of copy numbers from parents 
to children in CEPH family members. 
 
Table 4: PCR primer sequences from the 5bp indel ratio assay 
(rs5889219) used to amplify different lengths of the same location in the 
beta-defensins. All used the same forward primer. 
 
 
2.5.1: rs5889219 (5DEL) 
A 2bp/5bp deletion at chr8:7,363,859-7,364,008 about 10kb downstream of 
DEFB107 in the -defensin gene cluster was chosen to verify the copy 
numbers and the segregation of those copies in pedigrees.  Therefore, 
10ng of genomic DNA was amplified with the primers shown in table 4 
using PCR in 10X LD PCR mix as described in section 2.2.1.2. PCR 
amplification used similar annealing temperatures, 50 C over 22 cycles of 
Û&IRUVHFRQGVDQQHDOLQJWHPSHUDWXUHIRUVHFRQGVDQG C for 
VHFRQGVIROORZHGE\DVLQJOH³FKDVH´SKDVHRI C for 1 minute and 
70 &IRUPLQXWHVWRFRPSOHWH¶G$DGGLWLRQ$VIRURWKHUV\VWHPVWZR
parallel amplifications were carried out for each sample, one with a FAM 
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label, and the other with HEX; then 1µl from each reaction was added to 
10µl HiDi formamide with R-500 marker (Applied Biosystems), and 
analyzed by capillary electrophoresis as described in section 2.2.3.2. 
 
2.5.2: 9 indel 
In order to verify a 9bp insertion/deletion found in DEFB4 by sequencing, 
another indel ratio measurement assay was developed.  Products of 308bp 
and 298bp in size were amplified using FAM-labeled primer 9DELF 
(CCAAATGGAAGAATGGCGTA) and primer 9DELR 
(GTCCATTGGGTTCTCAAACT) with PCR in 10X LD PCR mix as 
described in section 2.2.1.2. Products were amplified using 23 cycles of 
Û&IRUVHFRQGV, 50 C for 30 seconds and 72 C for 1 minute, followed 
E\ D VLQJOH ³FKDVH´ SKDVH RI  C for 1 minute/72 C for 20 minutes to 
reduce levels of single-stranded DNA. There was only one amplification 
with a FAM label carried out for each sample; then 1µl from the reaction 
was added to 10µl HiDi formamide with R-500 marker (Applied 
Biosystems), and analyzed by capillary electrophoresis as described in 
section 2.2.3.2. 
 
2.5.3: Data analysis 
All peak areas corresponding to the 5DELI, 5DELII and 5DELIV, and 9DEL 
size ranges as mentioned earlier in table 4 and 2.5.2 respectively were 
recorded for both FAM- and HEX- labelled products using GeneScan and 
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Genotyper software (Applied Biosystems). A program to analyse copy 
numbers consistent with three peaks obtained from 5DEL assays was 
created by John Armour (Institute of Genetics, University of Nottingham) to 
HYDOXDWH D ³VTXDUHG GLIIHUHQFH VFRUH´ 5-X)2, where R is the measured 
ratio obtained from the peak area and X is the expected ratio being tested 
as explained in section 2.10.  
 
2.6: Restriction fragment length polymorphism (RFLP) at rs2203837 
Because of anomalous segregation in CEPH family 104 indicated by 
database genotypes, rs2203837 was specifically chosen to verify the 
genotypes in this family. PCR used forward primer 
CTTGGGGCTATGCATTGAGT and reverse primer 
TGTATGCACATACTGCCAACAC in general/ABgene PCR buffer as 
GHVFULEHG LQVHFWLRQZLWKF\FOHVRIÛ& IRUVHFRQGV C 
for 30 seconds and 70 C for 30 seconds. After that, the product (290bp) 
was digested with restriction enzyme MseI. The resulting DNA fragments 
were separated by agarose gel electrophoresis as described in the 2.2.3.1 
section. Fragments of 247, 16 and 27bp appear indicate C and fragments 
of 187, 60, and 27bp indicate T.    
  
2.7: Linkage analysis 
Linkage analysis of markers on chromosome 8 was performed by John 
Armour using the CHROMPIC option of CRIMAP (Lander and Green, 
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1987) and corresponding physical location inferred against the non-
inverted orientation of the region as represented in the UCSC March 2006 
Genome Assembly (hg18, NCBI Build 36). CRIMAP with the CHROMPIC 
option was used in this study to determine the parental origin of the 
FKLOGUHQ¶VDOOHOHIRUHDFKPDUNHUDV deduced from the available genotype 
information. Complete documentation about this analysis can be obtained 
from http://linkage.rockefeller.edu/soft/crimap/chrompic53.html.  
 
2.8: Sequencing strategy 
To follow up evidence of a dual location of the beta-defensins from the 
recombinations found in some CEPH families and verified by different 
assays, sequence analysis was carried out to compare sequences at 
different locations. Therefore, two gene loci in the beta-defensin cluster 
were chosen for sequence analysis in this study, DEFB103 and DEFB4.   
 
2.8.1: DEFB103 locus 
In order to successfully sequence the whole region of the DEFB103 locus, 
primers were designed as shown in table 5. Contrasting with the DEFB4 
locus, the full sequence of DEFB103 was amplified using only a single pair 
of primers to give a 1.8kb product; other internal primers were used to 
complete the sequence analysis. About 100ng of product was amplified 
using forward DEFB103F and reverse DEFB103R primers with PCR in 
10X LD PCR mix as described in section 2.2.1.2. PCR amplification was 
carried out for 35 cycles of 95 C for 30 seconds, 60 C for 30 seconds and 
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70 C for 4 minutes. Products then were separated on a 0.8% agarose gel 
to ensure the correct size has been amplified (2.2.3.1). AMPURE® PCR 
SXULILFDWLRQZDVSHUIRUPHGIROORZLQJ WKHPDQXIDFWXUHU¶VVWDQGDUGSURWRFRO
(Agencourt Bioscience Corporation, UK) to remove unincorporated 
primers, dNTPs, DNA polymerases and salts used that can interfere with 
sequencing. Sequencing was carried out as described in section 2.2.2 
using the primers in table 5. CLEANSEQ® Dye-terminator removal was 
carried out prior to sending for sequence analysis. The electrophoresis of 
automated DNA sequence reading was performed at DBS Genomic 
(Durham University, School of Biological and Biomedical Sciences).   
 
Table 5: PCR and sequencing primer sequences used for sequencing of 












2.8.2: DEFB4 locus  
Because a single-step PCR did not yield sufficient product from the DEFB4 
locus, two stages of PCR amplification were performed. Primary PCR 
amplification was carried out first to produce a 2.6kb product using forward 
DEFB4F and reverse DEFB4R primers. Then, two pairs of primers were 
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used in secondary PCR to specifically amplify two overlapping shorter 
regions inside the first product. The first short region was amplified using 
forward DEFB4Fb and reverse DEFB4R2 primers (1.8kb in size) and the 
other region was amplified using forward DEFB4F2 and reverse DEFB4R 
primers (1.6kb in size). Both of the above PCR amplifications were carried 
out using PCR in 10X LD mix as described in section 2.2.2.1. The first 
product was amplified with 35 cycles of 95 C for 30 seconds, 60 C for 30 
seconds and 70 C for 4 minutes. After that, the secondary PCR was 
carried out as described in section 2.2.1.3. Products were then analysed 
on a 0.8% agarose gel. AMPURE® PCR purification and CLEANSEQ® 
Dye-terminator were performed as for DEFB103 (2.8.1).  
 
Table 6: PCR and sequencing primer sequences used for sequencing of 


















2.9: Triplex system 
The PRT systems developed to measure the copy number variation in this 
study were combined in a triplex system. Three systems had successfully 
measured defensin copy number: two PRT systems, PRT107A and 
HSPD21, and 5DELR4 as an indel measurement system. All of these three 
systems were chosen because they produced different sizes of products 
when resolved in ABI capillary electrophoresis. Both PRT systems were 
amplified in one PCR with slight modification made to the PCR mixture and 
cycle. Both products were amplified using PCR in 10X LD PCR mix as 
described in section 2.2.1.2 using PRT107A PCR cycle as described in 
section 2.3.2. Meanwhile, 5DELIV indel measurement ratio was performed 
as a separate PCR amplification as described in 2.5.1 section using 
5DELIV primers (table 6). Routinely, two parallel amplifications were 
carried out for each system in every sample, one with a FAM or NED label, 
the other with HEX or NED; then 0.5µl to 1µl from each reaction were 
added together to 10µl HiDi formamide with R-500 marker (Applied 
Biosystems), and analyzed by capillary electrophoresis as described in 
section 2.2.3.2. 
 
2.9.1: Data analysis 
All peak areas or peak heights corresponding to HSPD21, PRT107A and 
5DELIV (peaks at 172bp and 180bp, 155bp and 157bp, and 123bp to 
128bp respectively) were recorded for both FAM/NED- and HEX/NED- 
labelled products using GeneScan and Genotyper software (Applied 
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Biosystems). Copy number of beta defensin was inferred using maximum 
likelihood analysis as described in section 2.10. Meanwhile, mean ratios 
for both PRT systems were used in conjunction with reference standards to 
calibrate each experiment as described in section 2.3.4. 
 
2.10: Maximum Likelihood Analysis  
A program written in C++ was created by John Armour (Institute of 
Genetics, University of Nottingham) to implement compound likelihood 
analysis. To run this programme, a set of results was used as an input file 
to evaluate the individual probability of getting the PRT or 5DEL results 
assuming each possible copy number from 2 to 9, and then to combine the 
likelihood results (by multiplying the results together for each copy number 
for each assay) to get the overall probability of the complete set of results 
for each of the possible copy numbers 2 to 9. The highest probability in 
each group is scaled to 1, and all other values expressed relative to that. 
The probabilities for each of the copy numbers 2 to 9 are calculated from 
PRT data assuming a normal distribution with a mean of the integer copy 
number and a standard deviation based on empirical observation (figure 
7) +RZHYHU WKH '(/ GDWD ZHUH HYDOXDWHG E\ FRPSXWLQJ D ³GLIIHUHQFH
VFRUH´ 5-X)2, where R is the measured ratio and X is the expected ratio 
being tested. Where there are two ratios (i.e. three peaks), the program 
uses the sum of the two difference scores. The reciprocals of the 
difference scores (so that the lower the difference score, the higher the 




Figure 7: An example of normal distributions for copy numbers of two (blue 
line), three (pink line), four (brown line) and five copies (light blue line). The 
dotted red line shows the estimated copy number from an example PRT 
assay, 4.2. Based on the assumption of normal distribution for each copy 
number, the most probable copy number for 4.2 is 4 copies. The table 
below (7b) shows that a copy number of N=5 (P5) is 0.001241 times as 
likely (i.e. about 800 times less likely) when compared to the probability of 






Chapter 3: Origins of Diversity at Human 
Beta-Defensin Copy Number 
 
3.1: Background of information  
Many recent studies have given most attention to the detection of copy 
number variation either as a whole genome study or on certain genes 
varying in copy number, and use a variety of assays to measure this 
variation in diploid genomes. Nevertheless, very few studies involve 
measuring haploid copy number and investigation of the origin of this 
haploid copy number variation. Consequently, there is very little known 
about the mechanism of generation of this copy number variation. This 
work aims at measurement of human beta defensin copy number variation 
in diploid and haploid genomes, and determination and characterization of 
the parental origin for the copy number variants, to understand the 
evolutionary processes that generate and maintain this variation in human 
populations.  
 
Meiotic recombination plays an important role in creating haplotype 
diversity in the human genome and has the potential to cause genomic 
rearrangements by nonallelic homologous recombination (NAHR) also 
known as ectopic recombination, and through changes triggered by 
recombination-initiation events, such as nonhomologous end joining 
(NHEJ) (Shaw and Lupski, 2004; Holloway et al., 2006; Turner et al., 
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2008). Giglio et al. (2001) reported that the beta defensin genes (at least 
250kb) involved in copy number variation are found on a large genomic 
repeat unit within a more complex copy number variation involving 
retroviral elements and olfactory repeat (OR) regions, collectively known as 
³5(3'´ IRU UHSHDW GLVWDO ,Q DGGLWLRQ Sugawara et al. (2003) found 
DQRWKHU VPDOOHU 25 UHJLRQ FDOOHG ³5(33´ UHSHDW SUR[LPDO DERXW 0E
proximal on 8p23.1 and sharing a high level of identity with REPD. The 
beta defensin cluster at chromosome 8p23.1, including DEFB4, DEFB103, 
DEFB104, DEFB105, DEFB106, DEFB107, but excluding DEFB1, are 
shown to vary in normal controls commonly between two to seven copies 
in diploid genome (Hollox et al., 2003; Hollox et al., 2005). Multiplex 
amplifiable probe hybridisation (MAPH) and semiquantitative fluorescence 
in situ hybridisation (SQ-FISH) found that cytogenetic duplications of 
8p23.1, regarded as euchromatic variants (EVs) in a previous study 
(Barber et al., 1998), had chromosomes carrying high copy number alleles 
between nine and twelve copies  (Barber et al., 2005). 
  
Usually for any gene present in two copies as shown in figure 8, one copy 
has been inherited from each parental genome at fertilization. However, for 
a gene present as four copies such as gene A (see figure 8), deducing 
haplotype copy number from each parental genome is not as simple as 
inferring haplotype from two copies. Any combination of haploid copy 
number, (one and three, two and two or zero and four) corresponding to 
the total number of four copies could be present.  
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Figure 8: An example of two chromosomes that represent reference 
paternal and maternal chromosome. In a) the figure shows an example of 
an individual that has two copies for gene A (coloured in red). In the normal 
situation we assume that one copy has been transmitted from each parent, 
so for this individual, one copy has been inherited from father and one 
copy from mother. In b), the figure shows an example of three different 
possibilities of haplotype combination deduced for gene A present as 4 
copies in an individual.  
 
In order to achieve the aims of this study, twenty-six multigenerational 
CEPH reference families have been used as described in section 2.1.1.2. 
The PRT assays at two different places, HSPD5.8 and PRT107A, 
combined with analysis of variant ratios at microsatellites EPEV-1, EPEV-2 
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and EPEV-3, and the multiallelic length polymorphism including the indel 
rs5889219, were used to type DNA from family members. The PRT assays 
were designed to measure the variable copy number per diploid genome. 
The microsatellite and multiallelic length polymorphism analyses were 
used to investigate the identity and parental origin of copy number 
haplotypes.  
 
3.2: Results  
3.2.1: Diplotype analyses    
           - Paralogue ratio test (PRT assays)  
An accurate assay was developed for copy number beta defensin region. 
Based on the principle that the test and reference amplicons should be as 
similar as possible, the problems of accuracy and reproducibility 
associated with multiplex PCR might be avoided. Deutsch et al. (2004) 
recently successfully exploited this principle to the diagnosis of trisomy 
when they found that some sequences present on chromosome 21 (for 
example) have nearly identical paralogues at another site in the genome. 
Therefore, a single pair of primers can be used to amplify both test and 
reference loci and distinguish them via minor differences of internal 
(reference) sequences. 
 
From this, Armour et al. (2007) developed a Paralogue Ratio Test (PRT) 
which was able to exploit the same advantages of amplifying both test and 
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reference loci with a single primer pair. They designed precisely-placed 
primers to amplify from copies of a diverged (low copy number) repetitive 
sequence at the copy-variable locus and at exactly one other (reference) 
location. As shown as in figure 9, a heat-shock protein pseudogene of 
~2kb (HSPDP3) is found ~2kb upstream of the DEFB4 gene and at 10 
locations elsewhere in the genome. Figure 10 shows a description of the 
PRT107A assay, amplifying a dispersed repeat copy near to DEFB107 
gene and at several locations elsewhere in the genome. Then primers that 
matched the copy on chromosome 8 and one other copy on the reference 
chromosome were designed exactly so that copies at other chromosomal 
locations had mismatches. As described in chapter two, section 2.3.1, 
2.3.2 and 2.3.4, both products were detected without other detectable 
fragments under the conditions used.  
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Figure 9: Principle of the HSPD5.8 assay at DEFB4. The top line shows 
the general structure of the repeat unit containing beta defensin genes 
(which has two inverted rather than tandem repeats in the March 2006 
assembly). The middle panel shows the location of genes SPAG11, 
DEFB4 and DEFB103-07 (coloured in black), together with the locations of 
assays (coloured in blue) used in this study. In the detailed display at the 
bottom, the primers amplify products from HSPDP3 pseudogene upstream 
of DEFB4 on chromosome 8, and from a reference copy on chromosome 
5, but have multiple mismatches with other copies of the element. In this 
way a single primer pair can be used to amplify two very similar products, 
one from near DEFB4, the other from chromosome 5. 
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Figure 10: The principle of the PRT107A assay at DEFB107 on 
chromosome 8, and from a reference copy on chromosome 11, with 
multiple mismatches with other copies of the element. In this way a single 
primer pair can be used to amplify two very similar products, one from near 
DEFB107, the other from chromosome 11.  
 
Beta-defensin copy numbers were first determined by the HSPD5.8 PRT 
assay in 324 individuals from twenty-six CEPH families, including 63 
unrelated individuals. As shown in figure 11, consistent with previous data 
(Hollox et al., 2003; Hollox et al., 2005), beta-defensin copy numbers were 
found to vary between two copies to eight copies per diploid genome with 
four to six copies being the most common.     
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Figure 11: Distribution of beta defensin copy numbers per diploid genome 
measured by HSPD5.8 PRT assay in 63 unrelated individuals collected 
from the whole set of CEPH families. 
 
3.2.2: Haplotype analyses 
3.2.2.1: Microsatellite analysis  
Microsatellites are tandemly repetitive stretches of DNA in which a short 
motif, from 1 to 5 nucleotides long, is repeated several times. They are 
common, easy to identify from genomic databases, and extremely 
polymorphic in the human genome. Microsatellite alleles are generally 
detected as DNA fragments of different sizes obtained after amplification 
with primers flanking the microsatellite region. Because of some problems, 
for example poor or non-VSHFLILFDPSOLILFDWLRQ LQFRPSOHWH¶-A nucleotide 
DGGLWLRQ DQG DPELJXLW\ FDXVHG E\ WKH ³VWXWWHU´ SKHQRPHQRQ FDXVHG E\
PCR slippage, microsatellite allele identification must be carried out after 
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very careful analysis. As PCR amplification produced very specific 
DPSOLILFDWLRQ LQ WKH H[SHFWHG VL]H UDQJH DQG DOPRVW FRPSOHWH ¶-A 
nucleotide addition, very careful attention was given to the stutter peaks 
caused by polymerase slippage during elongation as described in the 
chapter two, section 2.4.1. Below is an example for complex slippage 
patterns in EPEV2 which is not shown in chapter 2.  
 
For EPEV2, peak areas from 213bp to 264bp were recorded using 
GeneScan and Genotyper software (Applied Biosystems). However, in 
EPEV2, which has a complex internal sequence structure including repeat 
units of different length, a different approach of analysis to EPEV1 and 
EPEV3 has been carried out based on the peak patterns, sizes and 
slippage peaks. Very careful attention was taken to recognise and match 
the pattern because slippage peaks patterns had a complex relationship to 
the real peak pattern, up to 10-14bp different from the original peak as 




Figure 12: An example of the GeneScan electropherogram showing the 
stutter peaks and the main peaks in EPEV2. In this case there are four 
repeat units, one each containing alleles of 227bp and 264bp, and two 
containing 252bp alleles. The 264bp allele appears to lack a major (3/4bp) 
slippage product. 
 
In this study, microsatellites within this variable region were typed in CEPH 
families in order to verify the beta-defensin copy numbers which were 
indicated from the PRT assays. Therefore, microsatellite EPEV1 and 
EPEV3 were typed in 324 individuals (all the CEPH families) and 
microsatellite EPEV2 was typed for further analysis in only selected CEPH 
families. Microsatellite analysis was expected to give results consistent 
with the copy numbers from the PRT assay. The microsatellites could be 
used to confirm copy number measurements; for example, amplification of 




(4bp, to 248bp) 
Minor slippage 
(10/14bp, to 238/242bp) 
Minor slippage of 264bp allele 
(10bp, to 254bp) Minor slippage 
(10/14bp, to 213/217bp) 
Major slippage 
(3bp, to 224bp) 
227bp allele 
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number of 5. For an example, see the microsatellite EPEV3 profile of 
141601 in figure 15. Besides acting as a verification method for the PRT 
assay in determining the beta defensin copy numbers, these three 
microsatellites were also used to distinguish different copies of beta 
defensin repeats in segregation from parent to children, to determine the 
haplotype transmission. Figure 13 below shows the distribution of beta 
defensin copy number per haploid genome for 63 unrelated individuals 
(126 haplotypes) inferred from microsatellites EPEV1 and EPEV3. The 
frequency of beta-defensin copy numbers were found to vary between one 
copy and five copies per haploid genome, with two and three copies being 
the most common.  
 
Figure 13: Distribution of beta defensin copy numbers for 63 unrelated 
individuals (126 haplotypes) in CEPH families per haploid genome from 
microsatellites EPEV1 and EPEV3.  
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To follow haplotypes of beta defensin copy number variants from parents 
to children, segregation of the corresponding region of 8p23.1 from parents 
to the children in a set of 26 multigenerational CEPH families (Table 1) was 
first inferred with information from other local genetic markers typed in 
these same families, using the well-established CEPH genotype database. 
Below is one example of pedigree analysis on the AFM304ze9 marker for 
CEPH family 1416 (Figure 14). Eighteen of 26 CEPH families were 
obtained as three-generation pedigrees and the others were two 
generation only, including a total of 208 offspring in this study. A total of 
648 haplotypes have been examined in this study. 
 
 
Figure 14: Example of segregation from a single-copy marker in one of the 
CEPH families. This figure shows individual genotypes for family 1416 on 
marker afm304ze9 / (AC)n. The grandparental origin of each allele in each 
child is unambiguous in this example 
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To distinguish the haplotypes corresponding to the beta defensin copy 
number for each member in the CEPH families, alleles produced from 
EPEV1 and EPEV3 in the GeneScan electropherogram were collected and 
arranged in each CEPH family. Analysis of alleles at the EPEV1 and 
EPEV3 microsatellites in this region for most of CEPH families (Figures 15, 
16 and 17) showed one to three alleles per haplotype. As examples, in 
CEPH family 1416 (figure 15), they showed two and three alleles per 
haplotype, in CEPH family 1332, they only showed one and two alleles per 
haplotype (figure 16) and in CEPH family 1333, they showed two alleles 
per haplotype (figure 17). However, alleles at both EPEV1 or EPEV3 vary 
in copy numbers and are different between CEPH families; for example, 
the father in family 1416 has five copies of beta defensin from the 
HSPD5.8 PRT assay, one copy for each allele 137, 139 and 143 and two 
copies of alleles 141 from EPEV3, which indicates five copies, and one 
copy for each allele 169, 183 and 189 and two copies of alleles 181 are 
produced in EPEV1, which also indicates five copies (see Figure 15).  
 
Meanwhile, the father in family 1332 has three copies of beta defensin 
from HSPD5.8 PRT assay, two copies of allele 139 and one copy of allele 
141 from EPEV3, which indicates three copies, and one copy each of 
alleles 169, 181 and 185 from EPEV1, which also indicates three copies 
(see Figure 16). Furthermore the father in family 1333 who has four copies 
of beta defensin from HSPD5.8 PRT assay, one copy for alleles 137, 139, 
141 and 143 from EPEV3 which indicates four copies, and one copy for 
 80 
each allele 169 and 183 and two copies of alleles 187 from EPEV1, which 
also indicates four copies (see Figure 17). Therefore, the total numbers of 
beta defensin from both microsatellites are completely consistent with the 
HSPD5.8 PRT assay in most of the CEPH families used in this study and it 
also can begin to reveal the segregation of different copy number alleles 







Figure 15: An example of the alleles produced by EPEV1 and EPEV3 in 
the GeneScan electropherogram for CEPH family 1416 and the four 
possibilities of haplotype combinations in the children. Beta defensin copy 
number as measured by the PRT assay is shown in the last column after 
the individual number in the family, for example 141601(5). The first and 
second individual numbers are corresponding to the father and mother in 
this family and followed by children. Haplotype analyses for the whole 
family are represented in figure 21. 
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Figure 16: An example of the alleles produced by EPEV1 and EPEV3 in 
the GeneScan electropherogram for CEPH family 1332 with 5 
combinations in the children, showing a recombinant event in child 133205. 
Although no obvious change in copy number has occurred for child no. 
133205, the haplotype has generated diversity by a recombination event. 
Without a crossing over, this child should match either individual no. 
133204 or 133206, and get C or D from the mother. Haplotype analyses for 




Figure 17: An example of the alleles produced by EPEV1 and EPEV3 in 
the GeneScan electropherogram for CEPH family 1333 with five 
combinations in the children, showing a recombinant event in child 133306 
which showed five copies instead of four. This event has changed the beta 
defensin copy number in this child. Once again, this was another example 
in which the haplotype has been altered by a recombination event. Without 
a crossing over, this child should match individual no. 133304 or 133308, 
and get C or D from the mother. Haplotype analyses for the whole family 
are represented in figure 23. 
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3.2.2.2: Indel measurement assays 
Short insertion-deletion polymorphisms (indels) have been recognised as 
an abundant source of other genetic markers that are widely spread across 
the genome, though not as common as single nucleotide polymorphism. 
They may be as small as 1 bp or they may involve one or many exons or 
even the entire genes. Unlike microsatellite analysis, indel polymorphisms 
can be genotyped with a simple typing procedure and may be easily 
analyzed, as length differences of PCR products do not encounter the 
stutter problem as explained in section 2.4.1 and 3.2.2.1. Thus by taking 
advantage of a 2 bp/5 bp indel at chr8:7,363,859-7,364,008 (about 10 kb 
downstream of DEFB107) in the beta defensin gene cluster, beta defensin 
copy number variation was verified and segregation of those copy number 
haplotypes was followed in 26 CEPH pedigrees.   
 
As with microsatellite analysis, to distinguish the haplotypes corresponding 
to the beta defensin copy number for each member in the CEPH families, 
alleles produced from the rs5889219 indel in the GeneScan 
electropherogram were collected and arranged in each CEPH family. 
There were three distinct alleles. Although the rs5889219 indel is not fully 
informative (for example in figure 18, the 4 copy sample 141603 has 
variants in the ratio 1:1, compatible with any multiple of 2), this method 
provided valuable additional information by distinguishing repeat identities 
in the segregation analysis. Analysis of variants at the indel in this region 
for CEPH families (figures 18, 19 and 20) showed one to three alleles per 
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haplotype, which agreed with allele segregation from microsatellite 
analyses (Figures 15 - 17). The total numbers of alleles produced from the 
rs5889219 indel per haplotype in each CEPH family in this study were 
concordant with microsatellite alleles and also with the copy numbers 
measured from PRT assays.  
 
In family 1416, as shown in figure 18, father has five copies number of beta 
defensin from HSPD5.8 PRT assay and displays one copy for allele 119, 
two copies for each allele 123 and 125, consistent with five copies. Both 
haplotypes were deduced according to the allele segregation in the 
children. Therefore, haplotype A contains one copy each of alleles 119,123 
and 125, and haplotype B has one copy each of alleles 123 and 125. Even 
though the mother in this family also has five copies of beta defensin, the 
three alleles appear in different dosage. Haplotype C has one copy of each 
allele 123 and 125, and haplotype D has two copies of allele 119 and one 
copy of allele 125. All the children in this family have inherited non-
recombinant haplotypes from their parents. 
 
Meanwhile, in family 1332 (figure 19), both parents only have two alleles 
but in different dosage. Father has three copies of beta defensin from 
HSPD5.8 PRT assay, and showed one copy each of alleles 123 and 125 
for haplotype A and one copy of allele 125 for haplotype B. Mother, who 
has four copies of beta defensin from HSPD5.8 PRT assay, showed one 
copy each of alleles 119 and 125 for haplotype C and two copies of allele 
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125 for haplotype D. However, child 133205 has received a recombinant 
haplotype from mother. Even though this recombination event cannot be 
clarified from these data alone due to the uninformative alleles, the 
segregation of allele still can be inferred in this family and it agrees with 
allele segregation in microsatellite analyses.  
 
Additionally, E\ WDNLQJ DQ DGYDQWDJH RI  ES ES SRO\PRUSKLVP RI µ$¶
repeat found near to the 2 bp/5 bp indel location, an extended rs5889219 
indel analysis as described in section 2.5 was carried out on some of 
CEPH families who needed clarification for recombinant events. As an 
example, in family 1333, father who has four copies of beta defensin from 
the HSPD5.8 PRT assay, showed one copy each of alleles 169 and 171 
for haplotype A and one copy each of alleles 167 and 172 for haplotype B. 
Meanwhile, mother who has same copy number of beta defensin as father 
showed two copies of allele 167 for haplotype C and one copy each of 
alleles 167 and 169 for haplotype D. Child no. 133306 in this family has 
inherited a recombinant haplotype C/D from mother and this event has 
changed the beta defensin copy number in this child (Figure 20). Once 
again, this was another piece of evidence that the haplotype has generated 





Figure 18: An example of the alleles produced by indel analysis in the 
GeneScan electropherogram for CEPH family 1416 and the four 
possibilities of haplotype combinations in the children. Beta defensin copy 
numbers which are measured by the PRT assay are shown in brackets 




Figure 19: An example of the alleles produced by indel analysis in the 
GeneScan electropherogram for CEPH family 1332 with 5 combinations in 
the children, consistent with a recombinant event in child 133205 even 
though the alleles are uninformative, with the recombinant C/D haplotype 
indistinguishable in this assay from haplotype D. Compare microsatellite 
segregation in figure 13.  
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Figure 20: An example of the alleles produced by extended indel analysis 
in the GeneScan electropherogram for CEPH family 1333 with 5 
combinations in the children, showing a recombinant event in child 133306. 
This event has changed the beta defensin copy number in this child. Once 
again, this was further evidence that the haplotype has generated diversity 
by a recombination event. Without a crossing over, this child should match 
individuals 133304 or 133308, and get either haplotype C or D from the 





Figure 21: An overview of CEPH family 1416 over three generations. The 
individuals in this family are numbered from 1 to 14. The last four numbers 
(11, 12, 13 and 14) are grandparents. Beta defensin copy number 
measured by HSPD5.8PRT assay is shown in the bracket just after the 
individual number, for example (n=4). Both haplotypes are shown for each 
individual, either A, B, C or D. Each allele from microsatellite EPEV1 is 
shown as unboxed, alleles from microsatellite EPEV3 inside a box and 





Figure 22: An overview of CEPH family 1332. The individuals in this family 
are numbered from 1 to 16. The last four numbers (13, 14, 15 and 16) are 
grandparents (see figure 21 for detailed key). Child 133205 has a 






Figure 23: An overview of CEPH family 1333; for details of the symbols, 
refer to legends for figure 21 and 22. Child 133306 has a recombinant 
(C/D) maternal haplotype. 
 
3.2.3: Restriction fragment length polymorphism (rs2203837) 
The CEPH database genotypes for SNP rs2203837 in family 104 created 
an anomalous crossing over breakpoint. Therefore the genotypes for 
individuals 10407 and 10408 were directly verified using a PCR-RFLP 
assay and were subsequently corrected. After this correction, no 




3.2.4: Analysis of crossing over and copy number change  
In this study, recombination has been observed between the beta defensin 
repeat units by following the transmission patterns of three microsatellite 
and one multiallelic length polymorphism (indel) markers in CEPH family 
pedigrees as shown in the previous section. Each offspring haplotype was 
derived from one meiotic product from each parent and thus the frequency 
of crossing over within a particular chromosome interval can be quantified 
by examining many offspring. This approach has led to the detection of at 
least 24 out of 416 offspring with inherited recombinant haplotypes on 
which parental beta defensin repeats have been rearranged. Most of the 
offspring haplotypes have not changed the copy number, but in three 
cases a new copy number was found in the recombinant chromosome; for 
example, child 133306 in figure 17 and 20 receives a recombinant 
maternal chromosome carrying three repeat units, whereas children 
inheriting non-recombinant haplotypes in this family show that the mother 
has two two-copy haplotypes. Data in CEPH family 1341 also shows that 
children have received different (reciprocal) recombinant maternal 
haplotypes without changing the haplotype copy number (not shown). The 
breakpoint of crossing over between the beta defensin repeats has been 
examined in all CEPH families whose child/children have inherited 
recombinant haplotypes. From that analysis, all the breakpoints must 
happen between two beta-defensin repeat which are far apart from each 
other; the recombinations cannot all simply be occurring within a coherent 
block of beta defensin tandem repeats, as shown in figure 24. For 
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example, the breakpoint of the maternal crossover in 133306 is located 
about 3 Mb proximal to the March 2006 Genome Assembly position of beta 
defensin repeats. Linkage mapping was introduced in this study to facilitate 
the location of recombination breakpoints by testing for genetic linkage 
within the interval for already known markers on chromosome 8p23.1. 
During chromosome segregation, alleles on the same chromosome can be 
separated and go to different daughter cells. If the alleles are far apart on 
the chromosome, there is a greater probability that a crossing over will 
occur between them.  
 
However, for some recombinant cases, precise mapping of the beta 
defensin repeats could not be successfully determined because insufficient 
information was obtained from segregation analysis in the CEPH 
pedigrees. Therefore, those samples are labelled as unidirectional 
recombinants, based on the information from linkage analysis (Figure 24). 
In some transmissions, where parental repeats share many variants of the 
multiallelic markers typed and were not sufficiently informative to specify 
crossovers breakpoints. Due to this difficulty, the determined frequencies 
of these crossover processes are likely to be underestimates.   
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Figure 24: Genetic mapping of beta defensin repeats relative to crossover 
breakpoints in CEPH pedigrees, shown against genome assembly 
coordinates. The approximate locations of REPP and REPD are shown, as 
are the intervals containing the inversion polymorphism endpoints (Giglio 
et al., 2001; Antonacci et al., 2009). The crossovers indicate, at the top, 
selected unidirectional recombinants mapping the location of all repeat 
units on a haplotype, identified by family and individual name and parent of 
RULJLQ HJ´0´ LV WKH PDWHUQDO KDSORW\SH RI FKLOG  LQ IDPLO\ 
Below are shown selected crossovers which map repeats to the proximal 
and/or distal sites; the numbers of repeats mapping in each direction are 
indicated, and the hatched segments indicate uncertainty in the placement 
of breakpoints because of the lack of informative markers. Based on these 
data, beta defensin repeats can be mapped to the distal and proximal 
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intervals shown at the bottom (Figure adapted from (Abu Bakar et al., 
2009)). 
 
Although the segregation of some repeat units was consistent with the 
accepted location for the beta defensin genes, some of the beta defensin 
repeats segregating in these CEPH pedigrees could not be located at the 
established interval in the genome assembly within REPD at approximately 
chr8:6,900,000-8,150,000, but instead mapped to another site more 
proximally located on chromosome 8p (Abu Bakar et al., 2009). Analysis of 
crossover breakpoints in CEPH segregation data (table 7) showed that this 
second site must be bounded by AFMb294yg5 (chr8:11,515,050) distally 
and AFM205tb10 (chr8:14,724,000) proximally. There is no example of 
segregation inconsistent with location of beta defensin repeat units either 
at one or both of these sites on chromosome 8p. Abu Bakar and co 
workers (2009) also found that one crossover in child 135009 involved a 
breakpoint between two beta defensin repeats already mapped to the 
proximal site by crossovers in other children (135005, 135006 and 
135008); the placement of the breakpoint in 135009 is consistent with the 
results of other mapping data and allows further refinement of the proximal 





Table 7: Properties of 24 crossovers in CEPH pedigrees leading to 
reassortment of beta defensin repeat units. The numbers of copies of beta-
defensin at the proximal and distal sites are shown for the recombinant 
haplotype. The final column indicates events leading to a recombinant 
haplotype with a copy number not found on either parental haplotype. 
Maternal haplotypes in family 1362 are in the inverted orientation, and 
distal and proximal markers are shown in the corresponding order. 
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3.2.5: Targeted sequencing of variant repeats 
To further clarify the evidence for a dual location of the beta defensin 
genes from analysis of crossover breakpoints in CEPH families, sequence 
analysis was undertaken in this study to compare sequences of beta 
defensin at different locations. In this work, DNA sequencing analysis has 
been used to determine all the sequence polymorphisms in the targeted 
sequencing blocks (SBs) within CEPH pedigrees, whether common or rare 
in the population. By following the segregation of all the sequence variants 
found in the SBs in these families, we hoped to distinguish the sequences 
of beta defensin at two different locations on chromosome 8p23.1, and at 
the same time to verify the finding from the previous work on using 
segregation of other markers (refer section 3.2.2). Haplotypes for both 
locations of the beta-defensins have been constructed from sequence 
variants found in order to identify the similarity of nucleotide sequence. 
Therefore, two genes, which are DEFB103 and DEFB4 in the beta 
defensin cluster, were chosen as target loci for sequence variant analysis. 
There were 77 CEPH individuals, selected from the ten (out of twenty-six) 
CEPH families who showed recombinant events, as the subjects for this 
analysis. We chose the parents, all the recombinant children and some 
non-recombinant children that inherited different haplotypes for each of the 
ten CEPH families (table 8). As reference and sequence quality control, we 
included our four standard reference samples, C11, C18, C62 and C66, in 
this analysis.  
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Table 8: List of ten CEPH families and numbers of members that were 
selected for sequencing analysis. Selected individuals in the second 
column are according to the individual number in each family. Numbers 
coloured in blue indicate the parents, numbers in black the non-
recombinant children and numbers in red the recombinant children. 
CEPH families (no.of members 













This work aimed to look at the sequence variants for both DEFB103 and 
DEFB4 for the above subjects (see table 8). Analysis of ratios of sequence 
chromatogram peaks might not accurately reflect the correct copy number, 
but with the data from the PRT assay for diploid copy number and haploid 
copy number obtained from microsatellites and indel (5DELI) analyses, 
there is sufficient information to predict the copy number from sequence 
variant ratios as shown in figure 25. For example, the genotype of 133201 
(father) for the C/T variant has been deduced as two Cs and one T, while 
133202 (mother) only has T, predicted to be four Ts according to the copy 
number measured by the PRT assay. Inferring the sequence variants on 
each of haplotypes A, B, C and D was carried out by looking at the 
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children¶V alleles. For example children 133207 and 08 have inherited both 
alleles (C and T) compared to the other children who only inherited the T 
allele, however, child 133207 inherited haplotype D which is different from 
child 08 (haplotype C). Since mother only has T alleles, and children 
133204, 05 and 06 have only inherited T alleles from both parents, the two 
Cs have been traced to paternal haplotype A. Even though there is no T 
variant found in child 133205 who is known to inherit recombinant 
haplotype C/D from mother, it is still possible to map the variant into two 
locations on haplotypes according to the previous segregation and from 
other sequence variants in other locations as described later.       
 101 
 
Figure 25: Patch of sequence traces collected from DEFB103 shows 
segregation of one variant in CEPH family 1332 with five segregations in 
the children. Haplotype A in father has been deduced from the 
appearances of two Cs in children 133207 and 08. Segregation of this 
variant is consistent with a recombinant event in child 133205 even though 
the sequence alleles at this position are uninformative. Combination of 
more than one informative sequence variant in this analysis is able to 
distinguish the sequence for distal and proximal locations.  
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In order to illustrate clearly the use of sequencing analysis on the two loci 
within beta defensin repeats at distal and proximal sites, the identities of 
haplotypes in recombinant child 133205 have been drawn in figure 26. 
Three informative sequence variants have been deduced from each of the 
DEFB103 and DEFB4 loci for this family as shown in the tables (figure 26). 
Total number (unsegregated) of each variant in the second column 
corresponds to the beta-defensin copy number measured previously from 
other methods. As shown in figure 22, each copy of each sequence variant 
has been mapped to a haplotype, haplotype B or C/D, by consideration of 
the other children¶V haplotypes. Each of the alleles found in two 
microsatellite analyses and one multiallelic length polymorphism (indel) 
has been placed separately in a repeat unit according to their location in 
the genome assembly. For haplotype B, the exact location of the beta 
defensin is not known because there is no paternal recombinant; for 
simplicity, this copy is shown here at the established interval in the genome 
assembly (near to REPD). Moreover, allele 125 (in oval shape) from indel 
rs5889219 (5DELI), 139 (boxed) from EPEV3 and 169 from EPEV1 have 
been placed following the position in the genome browser. In haplotype 
C/D which has two copies, analysis of linkage showed that one copy is 
located at the distal and other copy at the proximal location. One copy at 
the distal location consists of allele 125 (oval) from5DELI, 143 (boxed) 
from EPEV3 and 191 from EPEV1, but allele 125 (oval) from 5DELI, 147 
(boxed) from EPEV3 and 187 from EPEV1 at the proximal location. This 
was supplemented first with the sequence variants collected from 
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DEFB103 locus and then with the DEFB4 locus for each repeat in each 
haplotype as shown in figure 26. This individual, for example, has 
illustrated different DNA sequence blocks between two sites which are 
TCTTGT at distal and TCACAC at proximal for haplotype C/D. Meanwhile 
haplotype B contained TCTTAC.  
 
 
Figure 26: Figure of child 133205 (3 copies) with the two haplotypes, B 
and recombinant C/D together with the allele patterns collected from two 
microsatellite and one indel (5DELI). Each allele from microsatellite EPEV1 
is shown as unboxed, alleles from microsatellite EPEV3 inside a box and 
allele from indel analysis inside an oval shape. Two tables on the top and 
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left corner describe the three informative sequence variants collected from 
DEFB103 and DEFB4 loci. Haplotypes B and C/D have been enlarged to 
show one copy of beta defensin at the distal location for haplotype B 
whereas for haplotype C/D, one copy at the distal and other copy at the 
proximal location. The location of each allele inside the repeat has been 
arranged according to the amplicon position in the genome assembly. The 
six letters drawn just after the third allele indicates the example of 
sequence variants found from sequencing analysis on DEFB103 and 
DEFB4 loci. All of the sequence variants have been mapped to the above 
locations by following the segregation in the children.    














Table 9: List of sequence variants annotated from the March 2006 
Genome Assembly for DEFB103 and DEFB4 loci (dbSNP release 130) 




3.2.5.1: DEFB103 locus 
For DEFB103, the full sequence of a 1.8kb product (chr8:7273588-
7275448, including the entire coding sequence) was successfully 
sequenced for 77 CEPH members as shown in table 8 by using two 
forward and three reverse primers (table 5). First, amplification from 
genomic DNA was carried out using DEFB103F and DEFB103R primers. 
Due to poly A and T repeats within this locus, three other primers were 
used as the internal sequence primers in order to obtain the full DNA 
sequence of DEFB103 locus. The product covered about 15 reported 
sequence variants in the March 2006 Genome Assembly for this locus 
(dbSNP release 130) as shown in table 9. Only three of these sequence 
variants were actually observed and segregated in the CEPH families for 
this analysis. In addition, this work detected one new variant which is not 
found in dbSNP. 
 
3.2.5.1.1: Segregation of the sequence variants found 
To determine the sequence variants at the two locations of beta defensin, 
segregation of observed sequence variants in selected CEPH families was 
analyzed by comparison with information from segregation of alleles in 
microsatellite and multiallelic length polymorphisms (indel) (see section 
3.2.2). The ratio of each sequence variant for each individual was 
estimated according to the copy numbers measured from PRT, 
microsatellite and indel assays. However, the non-linear signal at mixed 
positions in sequencing traces makes estimation of the ratio rather difficult. 
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As shown in figure 27 and 28, three and four sequence variants were 
successfully detected in families 1332 and 1333 respectively, and their 
haplotypes inferred in each individual. For family 1332, father (3 copies) 
showed two similar sets of sequence variants CCT for haplotype A and a 
set of sequence variants TCT for haplotype B. The first position of 
sequence variation, which is C (haplotype A) and T (haplotype B), has a 
ratio of 2:1. However, the second position (C) in this family appeared 
invariant, and differs from other CEPH families that show variants in this 
position.  The third position T also did not show polymorphism in the father 
but was variable in the mother. Therefore, the recombinant pattern could 
be followed in this family because the mother has a polymorphism in the 
third position.  
 
Moreover in family 1333 (figure 28), four variants including one which is not 
in dbSNP were collected to build the DNA sequences for each individual. 
Father 133301 has two two-copy haplotypes, but there is no recombinant 
event to determine the location of these two repeats even though two 
different sets of DNA sequences are shown in each haplotype. The first 
three positions are found to be polymorphic in father with the ratio of 3:1. 
The fourth position T did not show polymorphism in both paternal 
haplotypes. Meanwhile, mother 133302 carries polymorphism only at the 
first position, with a ratio of 2:2. Furthermore, two different DNA sequences 
for distal and proximal copies in haplotype C could be determined based 
on the recombinant pattern in child 133305, but haplotype D, appeared to 
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have two copies with the same alleles at this position. Furthermore, four 
forms of sequence haplotypes for three common variants have been 
observed in this work, TCA, TAT, TCT and CCT for DEFB103 locus (Table 
10). Three of them have been observed at both distal and proximal 








Figure 27: This is an overview of five members in CEPH family 1332 for 
DEFB103 locus. For details of the symbols, refer to legends for figure 18 
and 19. Each sequence variant can be assigned to haplotypes and 
ORFDWLRQV XVLQJ VHJUHJDWLRQ )RU H[DPSOH IDWKHU¶V 7 DW UV LV
assigned to haplotype B because of its appearance in children 133204 and 
6LPLODUO\PRWKHU¶V7DWUVLVDVVLJQHGWRKDSORW\SH&IURPLWV




Figure 28: An overview of five members in CEPH family 1333 for 
DEFB103 locus. For details of the symbols, refer to legends for figure 18 
and 19. Each sequence variant can be assigned to haplotypes and 
ORFDWLRQV XVLQJ VHJUHJDWLRQ )RU H[DPSOH IDWKHU¶V & DW UV LV
assigned to haplotype A because of its appearance in child 133304 and 
06, and A at rs62636849 is assigned to haplotype B because of its 
appearance in children 133303. MeanwKLOHPRWKHU¶V&DW UV LV
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assigned to haplotype D from its appearance in 133304, and to a proximal 
location from its appearance in 133306.  
 
Table 10: Sequence variants annotated from the March 2006 Genome 
Assembly for DEFB103 (dbSNP release 130). Haplotype blocks 
constructed from 3 sequence variants (marked with red), are observed at 
distal and proximal sites; three similar sequence variants are found at both 
sites (TCA, TCT and CCT).  
 
 
3.2.5.2: DEFB4 locus 
Inspection of the sequence variants at more loci is needed to have strong 
evidence of variance in haplotype blocks at the two sites of beta-defensin. 
Consequently, DEFB4 was chosen as another locus to be sequenced. In 
this study, a 2.5kb product of DEFB4 (chr8:7789378-7791843) was 
sequenced in 77 CEPH members as shown in the table 8. As explained in 
section 2.8.2, amplification of the DEFB4 locus is not as simple as the 
DEFB103 locus, due to unequal distribution of GC-rich and AT-rich 
regions, and a block of AGGG repeats, which is known as microsatellite 
(EPEV2) in our experimental study. Therefore, two overlapping nested 
PCRs were performed to give primary amplicons (about 1.6 to 1.8 kb), and 
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several internal primers were designed as shown in table 6 in order to 
obtain the complete sequence at this locus.  
 
Moreover, the product covered 25 reported single nucleotide 
polymorphisms, given in the March 2006 Genome Assembly for this locus 
(dbSNP build 130) as shown in table 9. A 9 base insertion/deletion (indel) 
was found from DEFB4Fb and DEFB4R2 sequencing primers 
(chr8:7789958-7789967) within this locus which could be used as the basis 
of allele-specific PCR to define association of variants within each repeat 
copy. In addition, ratio analysis on the 9 indel has been carried out as 
described in section 2.5.2 to identify the 9 indel genotypes for the CEPH 
members. Consequently, all of the collected single sequence variant and 9 
indel ratio analysis data could be inferred together for each haplotype in 
the CEPH members as shown later. In the meantime, four primers, 
DEFB4InsF, DEFB4IndR, DEFB4InsR and DEFB4Fb were designed to 
specifically amplify only either insertion or deletion allele within the DEFB4 
locus. Furthermore, examination of all the sequence variants found from 
other primers (DEFB4Fb, DEFB4R2, DEFB4F2 and DEFB4R) has been 
performed and the DNA sequence for each haplotype has also been 
deduced in CEPH members.  
 
3.2.5.2.1: Segregation of the sequence variants found  
Deducing complete haplotypes from DEFB4 sequence variants found in 
CEPH families was technically quite challenging, due to failed sequence of 
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some family members, and time constraint in order to complete the DEFB4 
analysis. Nevertheless, segregation of the 9 indel polymorphism based on 
ratio analysis has successfully been carried out in 10 CEPH families (data 
not shown). Both insertion and deletion forms have been observed at both 
sites (distally and proximally). Their transmission patterns also agree with 
the previous segregation from other markers. In order to determine the 
haplotype block at distal and proximal sites from this locus, the 9 indel 
segregation has been joined with the sequence variants. However, the 
haplotype blocks could only be deduced in CEPH family 1332 when taking 
into consideration the information sequence variants and the 9 indel from 
the DEFB4 locus. The father (3 copies) in family 1332 (figure 29) showed 
three similar sets of sequence variants TTG; two for haplotype A and a set 
of TTG for haplotype B. However, 9 indel discriminated the two repeats for 
haplotype A. Meanwhile, one copy of the insertion has segregated together 
with TTG sequences in haplotype B, and is transferred to children 133204 
and 05. The mRWKHU¶V KDSORW\SHV DUH IDU PRUH XVHIXO as all of the three 
sequence variants are informative. Mother showed two different sets of 
sequence variants, CCA distally and TTG proximally for haplotype C 
(because of its appearance in child 133205). The indel discriminated the 
two similar sequence sets TTG for haplotype D because of the 
recombinant pattern in this family. There were three haplotypes when both 
9 indel and other variants are considered in the analysis which are TTC 
with deletion, CCA with deletion and TTG with insertion (Table 11 or Figure 
29). Even though three different haplotype blocks were observed as shown 
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in table 11, due to the relatively sparse analysis obtained for DEFB4 locus, 
there are no examples of identical haplotypes at both sites (distal and 
proximal) as seen in DEFB103 analysis; thus, combining haplotypes from 





Figure 29: This is an overview of five members in CEPH family 1332 
including results from sequencing analysis on DEFB4 locus. For details of 
the symbols, refer to legends for figure 18 and 19. Each sequence variant 
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can be assigned to haplotypes and locations using segregation. For 
example, one copy of insertion from IDWKHU¶V 9 indel is assigned to 
haplotype B because of its appearance in children 133204 and 05. 
Meanwhile, each of mRWKHU¶V KDSORW\SHV & DQG ' KDYH one copy of 





















Table 11: Sequence variants annotated from the March 2006 Genome 
Assembly for DEFB4 (dbSNP release 130). Haplotype blocks constructed 
from 3 sequence variants and 9 indel (marked with red), observed at distal 
and proximal sites. Two different haplotypes are observed for the two distal 




In this study, by utilising highly polymorphic markers (microsatellites and a 
multiallelic indel) CEPH pedigree analysis has provided valuable 
information on the segregation of the copy number variants. The various 
other CNV measurement methods available, with the exception of 
Southern blot hybridization of pulsed-field gels (Yang et al., 2007) and of 
some fibre-FISH analyses (Perry et al., 2007), determine diploid copy 
number for multiallelic loci but do not report the real co-dominant 
genotypes (i.e., in terms of component haplotypes) in an individual.  There 
is still less information on the copy number location and the parental origin 
of copy number. Furthermore, for the human beta-defensin repeat, in 
which the variation involves a large physical distance, analysis of the copy 
number variants descending through a pedigree provides a means to 
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dissect the copy number variation into its constituent haplotypes. 
Surprisingly, this approach not only verified the diploid copy number of 
beta defensin measured by PRT, but also determined that diploid copy 
number was the sum of contributions from variants at each of two distinct 
locations. Even though some of the variants might be not informative to 
distinguish copy number identities, amplification from different locations of 
the variants in the region of interest have clarified the individual genotype 
for the copy number variants and also to helped to determine whether copy 
number inferred was the product of meiotic recombination. Transmission of 
alleles within the beta-defensin region in CEPH families demonstrated that 
recombinant events help in mapping the location of the alleles contributing 
to the copy number.  
 
By using a genetic approach in the CEPH pedigrees and subsequent 
linkage analysis, this work has shown that homologous recombination is 
involved in beta-defensin genome exchange patterns in the individual 
meioses. From the recombinant chromosomes, the polymorphic beta-
defensin region has been identified and mapped explicitly into two loci 
separated by several Mb of single-copy sequence to locations consistent 
with the REPP and REPD repeat regions. This study has shown that beta-
defensin copy number is diversified by this recombination mechanism. 
Nevertheless, this 8p23.1 region that contains the beta-defensin cluster 
has been shown to be involved with another structural polymorphism, a 
large inversion (Giglio et al., 2001; Antonacci et al., 2009). Giglio et al. 
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(2001) demonstrated not only the involvement of OR gene clusters in 
mediating common chromosome rearrangements, but also some recurrent 
rearrangements, such as the recurrent inversion, indicating the possibility 
of developing a profile of the individual risk of having progeny with 
chromosome rearrangements by looking at the 8p23.1 region. In this work 
WKH LQYHUVLRQ SRO\PRUSKLVP FRXOG EH D PHFKDQLVP IRU µWUDQVSRUWLQJ¶ WKH
beta-defensin repeats between the distal location and the proximal location 
DW5(33ZKLFKFRXOGDULVHE\IUHTXHQWµIOLSSLQJ¶RIWKLVVHTXHQFHEHWZHHQ
different inversion states to sometimes include, and sometimes exclude, 
beta-defensins at each location. There were examples of zero, one or two 
copies of beta defensins at the proximal location, and zero, one and three 
at the distal location observed in this study (see Figure 19 and 20).  
 
In addition, sequence analysis on DEFB4 and DEFB103 in these CEPH 
pedigrees, using segregation in recombinant offspring to map sequence 
variants to the distal or proximal sites, has clearly verified the evidence 
from microsatellite and indel alleles that sometimes the same alleles and 
sequence variants can be found at both proximal and distal sites. In figure 
24, sequence polymorphism at 3 positions found in the mother for family 
1332 has shown that T, C and A mapped at both proximal and distal sites 
from their appearance in child 133205. Insertion and deletion forms of 9 
indel could also each be found at both sites from their appearance in 
children 133205 (Figure 29).  
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3.4: Conclusion 
In conclusion, human beta defensin copy number in 26 reference CEPH 
families was measured accurately by using two PRT assays, HSPD5.8 and 
PRT107A, and confirmed by microsatellite and indel analyses. 
Measurement of variation in copy numbers of beta defensin clarified that 
there are commonly between two and eight copies per diploid genome, 
and one copy to five copies per haploid genome, with two and three copies 
being the most common haploid copy number. The additional methods 
used in this study, microsatellite analysis and multiallelic length 
SRO\PRUSKLVP³LQGHO´DVVLVWHGLQORRNLQJDWWKHWUDQVPLVVLRQRIDOOHOHVDQG
segregation patterns for the whole CEPH families. Recombinant events 
between homologous chromosomes were discovered as a simple 
mechanism for exchanging the beta defensin material between 
KRPRORJRXVFKURPRVRPHVZKLOH LQIHUULQJDFKLOG¶VKDSORW\SHDQGDOORZHG
the location of beta defensin repeats to be mapped relative to the position 
of crossovers inferred from the CEPH segregation database. Notably, 
some of those recombinant events have produced a new haplotype that 
results in changes in the copy number of beta defensin, at a frequency 
about 0.7% per gamete (3 out of 416), whereas most of the recombinants 
do not change the copy number. Finally, this study concludes that beta-
defensin repeats can be in two positions in the human genome. One of 
these sites is consistent with the location in distal 8p23.1 indicated on the 
genome assembly, but there is also a separate location about 5Mb 
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proximally. The existence of two distinct loci for variation in beta-defensins 
is unusual, and may be the only such example in the genome, but it 
nevertheless illustrates that mechanisms of copy number variation may be 


















Chapter 4: Development of a Multiplex PRT 
Measurement System for Beta-Defensin  
Copy Number Variants 
 
4.1: Background information 
Standard methods of molecular genetic analysis at individual genetic loci, 
including Southern blotting, cytogenetic methods, and PCR-based 
approaches are the best known methods for mapping structural variants at 
different resolution. Screening of single nucleotide polymorphisms in 
certain individual genomes has been extensively utilised in order to 
analyze the genetic determinants of complex traits and common disorders. 
This approach was mainly based on their abundance in the genome, and 
their use was boosted by the technological development of tools for high-
throughput analysis of SNP variants. Until recently, the roles of SNPs in 
human disease have been focused exclusively in gene mapping studies. 
Subsequently, development of the latest generation of array comparative 
genomic hybridization, next generation sequencing and SNP genotyping 
arrays have accelerated the discovery of structural variations. Numerous 
studies have noted the greater extent of various types of structural 
genomic variation, ranging from 100 bp to 100 Mb, than previously 
expected (Iafrate et al., 2004; Feuk et al., 2006). Furthermore, recognition 
of the critical role of structural genetic variation in gene expression and 
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disease phenotype is growing rapidly, including the effect of copy number 
variants (CNVs) (McCarroll and Altshuler, 2007).   
 
Early work on determination of beta-defensin copy number variants has 
begun by using a combination of different methods independently, 
Multiplex Amplifiable Probe Hybridization (MAPH), semiquantitative 
fluorescence in situ hybridization (SQ-FISH), segregation and 
microsatellite analysis. These were able to detect the distribution of beta-
defensin copy number per diploid genome as mentioned before and 
deduced that individual chromosomes had between one and seven copies 
of this repeat unit (Hollox et al., 2003). Later, in another work which was 
the first study on the association of beta-defensin and a clinical phenotype 
using (MAPH) and microsatellite analysis, Hollox et al. (2005) examined 
copy number in a cohort of patients with cystic fibrosis (CF), with no 
association found. Subsequently, Fellermann et al. (2006) analysed the 
human beta-defensin 2 (DEFB4) gene in healthy individuals and patients 
with &URKQ¶VGLVHDVHDQGulcerative colitis using genome wide DNA copy 
number profiling by array-based comparative genomic hybridization and 
quantitative polymerase-chain-reaction approach. They proposed that a 
lower DEFB4 gHQHFRS\QXPEHUSUHGLVSRVHVWRFRORQLF&URKQ¶VGLVHDVH
Even though the results fit with a model that presents susceptibility alleles 
as reducing the antimicrobial barriers in the gut, this work was only 
reported from a non-replicated study based on small sample numbers. 
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Hollox et al. (2008) used three combined methods to diplotype beta 
defensin copy number: paralogue ratio tests (PRT), restriction enzyme 
digest variant ratios (REVDR) and MAPH in investigation of the 
relationship between beta-defensin gene copy number and risk of 
psoriasis. The authors have similar PRT methods (Armour et al., 2007) as 
in the previous study (refer sections 2.3.1 and 3.2.1), and compared these 
data to the typing from MAPH and ratios of multisite variants (REVDR) 
mapping around the DEFB4 gene to determine copy number of beta 
defensin repeat per diploid genome. Copy number data from DEFB4 are 
consistent with variation of integer copy numbers, so typing by more than 
one method or repeat typing can often improve results and produce clear 
clusters of samples falling into each integer copy number diplotype (Hollox 
et al., 2008).  
 
To fill the gap arising from the absence of an accurate typing method for 
measurement of beta-defensin copy number variants, a triplex system has 
been developed in this study. This system consist of two paralogue ratio 
tests (PRTs); PRT107A (section 2.3.2) and HSPD21 (section 2.3.3), and 
5DELR4 which is an extended rs5889219 indel analysis as described in 
section 2.5. Similar to the other two PRT assays described previously, 
HSPD21 primers are designed precisely to amplify from copies of a 
diverged (low copy number) repetitive sequence at the copy-variable locus 
3kb upstream of DEFB4 on chromosome 8, and at only one other 
(reference) location (from chromosome 21) as shown in figure 30. As 
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described in chapter two, sections 2.3.1, 2.3.2 and 2.3.4, both products 
were detected without other detectable fragments under the conditions 
used.  
 
Figure 30: Principle of the HSPD21 assay at DEFB4. The top line shows 
the general structure of the repeat unit containing beta defensin genes 
(which has two inverted rather than tandem repeats in the March 2006 
assembly). The middle panel shows the location of genes SPAG11, 
DEFB4 and DEFB103-07 (coloured in black), together with the locations of 
assays (coloured in blue) used in this study including HSPD21-PRT. In the 
detailed display at the bottom, the primers amplify products at 3kb 
upstream of DEFB4 on chromosome 8, and from a reference copy on 
chromosome 21, but have multiple mismatches with other copies of the 
element. In this way a single primer pair can be used to amplify two very 
similar products, one from near DEFB4, the other from chromosome 21.  
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In each sample which underwent this triplex system, a collection of traces 
as shown in figure 31 was obtained that consisted of two PRT assays 
(PRT107A and HSPD21) and one indel assay (5DELR4). Due to the size 
differences, products from each assay could be analyzed in the same 
capillary. In the first row, this person has an allele ratio of 2:1 for 5 DELR4, 
and is measured as 3 copies from both PRTs. In the second row, this 
person has allele ratio 1:1 from 5DELR4, and 4 copies from both PRTs. In 
the last row, this person with allele ratio 2:2:1 from 5DELR4 has 5 copies 
from both PRTs. These traces showed consistency between three assays 
that could be used to determine the copy number by a single assay. 
Likelihood analysis as described in section 2.10 was carried out to allow 
evaluation of the joint probability of all the data (two PRTs and 5DELR4) 
observed for a given sample for a likely integer copy number together with 
evaluation of the statistical confidence. This PRT-based triplex assay has 







Figure 31: This figure shows the traces obtained from the triplex system, 
(two PRT assays (PRT107A and HSPD21) and one indel assay (5DELR4). 
Predicted copy number for each individual in these traces from this system 
is shown to the left of the box. Inside the box, there are two peaks visible 
for each PRT; one from the reference locus and one from the variable 
(test) locus. The genomic ratio of test:reference copies for each PRT is 
shown just before the peaks. For the indel, there are up to three distinct 
alleles (123, 125 and 127bp) detected in this experiment. The genomic 
ratio from each peak to the smallest peak is also shown here just after the 
peaks.  
 
Crohn's disease is an inflammatory disease of the intestine that may affect 
any part of the gastrointestinal tract from mouth to anus, causing a wide 
range of symptoms. It usually causes abdominal pain, diarrhoea (which 
may be bloody but less common), vomiting, or weight loss that results from 
malabsorption but may also cause complications outside of the 
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gastrointestinal tract to create other chronic inflammatory features such as 
skin rashes, arthritis and inflammation of the eye (Baumgart and Sandborn, 
2007). Crohn's disease is also recognized as an autoimmune disease, in 
which the body's immune system attacks the gastrointestinal tract, causing 
inflammation; it is classified as a type of inflammatory bowel disease. The 
IBDs are common causes of chronic gastrointestinal disease in developed 
countries, with reported prevalence rates of 1 in 250 in Northern European 
populations (Rubin et al., 2000). They comprise two main forms; &URKQ¶V
disease (CD) which is often localized with a discontinuous distribution 
along the intestine, and ulcerative colitis (UC) which always involves the 
rectum and is continuous in distribution. In adults, CD is often limited to the 
ileum (the last portion of the small bowel) and/or colon whereas CD in 
children is typically more extensive. CD is classified into two groups of 
SKHQRW\SHFRORQLFDQGLOHDO&URKQ¶VGLVHDVH 
 
The etiology of CD and UC is complex and remains elusive, but 
epidemiological data conclusively point to an impaired immune response 
against the bacterial flora in a genetically susceptible host (Loftus, 2004). 
Investigation of familial clustering of inflammatory bowel disease, ethnic 
variability and twin studies have provided strong evidence to support a role 
for inherited factors, which are found to be much stronger for CD than UC 
(Russell et al., 2004; Van Limbergen et al., 2009). Both techniques of 
candidate gene analysis and genome wide scanning (GWAS) have been 
used to identify genes that influence disease susceptibility and progression 
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in CD. Candidate gene studies have involved linkage analysis, case-
control studies and family-based transmission disequilibrium testing 
(Russell et al., 2004; Van Limbergen et al., 2009).  
 
Hugot et al. demonstrated the first IBD susceptibility locus, IBD1 on 
chromosome band 16q12 (Hugot et al., 1996). Closer examination of the 
IBD1 region allowed identification of frameshift mutations in the NOD2 
(nucleotide-binding oligomerization domain 2) gene which was later 
renamed CARD15 (caspase activation recruitment domain 15) as the first 
susceptibility gene for CD (Ogura et al., 2001). This gene is a member of 
the innate immunity system which belongs to the family of pattern-
recognition receptors (PRRs) and comprises a central nucleotide binding 
domain (NBD), N-terminal caspase recruitment domains, and a leucine-
rich repeat (LRR) region that recognize bacterial peptidoglycans; they are 
among the first lines of defence against microbial flora in the 
gastrointestinal tract (Inohara et al., 2002).  
 
Since the discovery of NOD2 as a CD susceptibility gene, the role of the 
innate immune system in IBD has been studied extensively, and mutations 
in a number of genes of the innate immunity pathway have been found to 
be associated with CD susceptibility. In addition to IBD1, IBD2 at 
chromosome band 12p13, IBD3 (chromosome 6p21), IBD4 at 14q11, IBD5 
(15q13), IBD6 (19p13), IBD7 (1p36), IBD8 (16p) and IBD9 (3p26) were 
identified in genome wide linkage screens involving 1200 family pedigrees 
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affected by IBDs (Steven and Yin Yao, 2004). A SNP in the TNFSF15 
gene at chromosome 9q32 has also been reported to be associated with 
CD (Yamazaki et al., 2005). The TNFSF15 gene encodes tumor necrosis 
factor (TNF) superfamily member 15. This gene is upregulated in mucosal 
cells lining the intestine of patients with CD.  
 
In 2009, Van Limbergen and colleagues reviewed more than 30 distinct 
genomic loci which are involved in JHQHWLFVXVFHSWLELOLW\WR&URKQ¶VGLVHDVH
(CD)  from epidemiological data, based on concordance information in 
family studies, via linkage analysis to genome wide association studies 
(Van Limbergen et al., 2009). They have described the loci which have 
most influenced the understanding of CD pathophysiology and/or provide 
strong therapeutic potential. These loci including innate pattern recognition 
receptors (NOD2/CARD15, TLR4, CARD9), and genes involved in the 
differentiation of Th17-lymphocytes (IL-23R, JAK2, STAT3, CCR6, 
ICOSLG), autophagy (ATG16L1, IRGM, LRRK2), maintenance of epithelial 
barrier integrity (IBD5, DLG5, PTGER4, ITLN1, DMBT1, and XBP1) and 
the orchestration of the secondary immune response (HLA-region, 
TNFSF15/TL1A, IRF5, PTPN2, PTPN22, NKX2-3, IL-12B, IL-18RAP, 
MST1).  
 
Nevertheless, Wehkamp and colleagues (2005) have proposed that the 
imbalance between the commensal flora and the host epithelium may be 
crucial tR&URKQ¶VGLVease pathogenesis. &URKQ¶VPXFRVDPD\RIWHQEHWKH
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target of various infections in which there may be a primary defect in the 
peptide barrier of intestinal antibiotic defensins, which protect the normal 
mucosa extremely efficiently against adherent or invasive microbes as 
illustrated in figure 32 (Wehkamp et al., 2005). Thus, a comprehensive 
understanding of these functionally relevant peptides is essential for the 
understanding of mucosal biology, and an impaired balance of these 
effector molecules might explain various aspects of pathogenesis in IBDs 
(Wehkamp et al., 2005). Defensins are endogenous antibiotic peptides that 
produce a chemical barrier at the epithelial surface, and their respective 
insufficiency may lead to bacterial adherence to the mucosa, slow 
invasion, and secondary mucosal inflammation (Wehkamp et al., 2005). 
These authors suggested that the main clinical phenotypes of IBDs, ileal 
DQG FRORQLF &URKQ¶V GLVHDVH could be linked to a characteristic lowered 
defensin profile. They found ileal disease is associated with NOD2 
mutations that have been shown to reduce the expression of the main ileal 
alpha-defensin molecules (HD5 and HD6) in Paneth cells, and conversely, 
&URKQ¶VFROLWLV LVDVVRFLDWHG with induction of the epithelial beta-defensins 





Figure 32: Simplified model of the normal reaction (upper) in the healthy 
intestine as well as the defective antimicrobial barrier in the intestine of 
&URKQ¶VGLVHDVHSDWLHQWV ,Q WKHKHDOWK\JXW WKHPLFUREHVFDQQRW LQYDGH
the mucosa because of an effective antimicrobial barrier (defensins). In 
&URKQ¶V GLVHDVH ORZHU HVSHFLDOO\ LQ SDWLHQWV ZLWK LOHDO disease, this 
antimicrobial barrier is disturbed, and bacteria can invade the mucosa. 
According to this hypothesis, a bacterial invasion as a result of a defensin 
deficiency is the primary reason for the secondary inflammation (taken 





Investigations on the relationship between human defensin genes and CD 
phenotypes have continuously been studied when all these defensins are 
found to be coordinately underexpressed in colonic CD. Furthermore there 
was a study on the human beta-defensin copy number changes that are 
positively correlated with the expression of HBD-2 in leucocytes (Hollox et 
al., 2003). Fellermann et al. (2006) therefore measured DNA copy number 
in the beta-defensin cluster in two independent cohorts with inflammatory 
bowel diseases and related it to mucosal HBD-2 gene expression. They 
concluded from a small number of samples that a lower HBD-2 gene copy 
number in the beta-defensin locus predisposes to colonic CD, most likely 
through diminished beta-defensin expression (Fellermann et al., 2006). 
Meanwhile, Bentley and co workers have challenged those data with their 
contrasting results which indicate that elevated DEFB4 copy number is a 
risk factor for CD (irrespective of intestinal location) (Bentley et al., 2009). 
To overcome these issues, we therefore proposed our triplex assay as the 
applicable technique to be applied on large case-control association 
VWXGLHV RI &URKQ¶V GLVHDVH to be compared with the previous studies. 
Understanding the beta-defensin copy number roles in this disease would 
also drastically change the understanding of therapy, and new strategies 






4.2.1: Testing and quality control 
For each single experiment of typing copy number at the beta-defensin 
region in this study, standard samples from ECACC panel 1, C11 (n = 4), 
C18 (n = 3), C62 (n = 5) and C66 (n = 6) which always gave reproducible 
results from several PRT assays, and for which the beta defensin copy 
number has been clarified with other methods and other laboratories, were 
included as internal controls and used for calibration of the beta-defensin 
copy number from PRT assays as shown in figures 4a, 4b and 4c (section 
+RZHYHUGXHWRWKHDSSHDUDQFHRIDVSXULRXVµG\HSHDN¶close to 
one of the HSPD21 peaks, as shown in figure 33, and after comparing the 
quality of data produced from peak area and peak height (data not shown), 
all the data produced from this system in this study were collected by using 
peak height. All the three dye peaks are shifted from the true peak sizes as 
shown in figure 33(a) and 33(c). Hence, one of the HSPD21 PCRs used 
NED labelling and produced a range of mobilities close to the NED dye 
peak, and if there is a shift in the NED dye peak to overlap with the real 
peak of HSPD21, data from peak height seems to be most reliable for 




Figure 33: The appearance of dye peaks produced from three different 
labels on the multiplex PRT-based system, FAM, HEX and NED with their 
apparent sizes. a) Location of dye peaks from FAM, NED and HEX in a 
blank control with mobilities corresponding to apparent sizes of 117 bp, 
167 bp and 172 bp respectively. b) The appearance of dye peaks is similar 
for sample 1 compared to blank, but in c) sample 2 showed relatively 
shifted dye peaks from the original location in the blank.  
 
Beta defensin typing for these four standard samples with the triplex 
system was investigated by looking at the clustering of PRT107A and 
HSPD21 ratios as shown in figure 34. As expected, both typings from PRT 
assays in this system produced clear clusters of results corresponding to 
copy number diplotypes of 3, 4, 5 and 6, either in the analysis of London 
VDPSOHV RU (GLQEXUJK VDPSOHV IRU &URKQ¶V GLVHDVH 3HUKDSV GXH WR WKH
different methods of preparation for standard DNA samples, very tight 
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clusters are observed for Edinburgh data compared to London data for 3 
and 4 copies, but the clustering is similar for 5 and 6 copies. For C11 
samples (4 copies) the cluster does not fall exactly at n = 4.0 for PRT107A, 
and we assume the cause was some variation in the degree of 
amplification from a third locus to yield products indistinguishable from the 
reference locus product (chromosome 2); this has only one mismatch, and 
variable amplification from this source might make the yield of product from 
the reference locus appear more variable for PRT107A. When we used 
that ratio to predict the copy number for this sample in PRT107A, the 
unrounded copy number appeared less than 4.0 but still close to that 
integer. Nevertheless, there were 326 tests of the above reference 
samples typed from the triplex system for two cohorts and an incorrect 
copy number was called on only 11 occasions in all cases involving 5- and 
6- copy samples. This suggested that the per-test error rate is of the order 
of 3-4%. The triplex system then was also applied to the collection of 
reference samples from ECACC panel 1 and panel 2.     
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Figure 34: Results produced by two PRT assays (PRT107A and HSPD21) 
in the triplex system for multiple typing of four standard samples. (a) 
Scatterplot of triplex results that agree between PRT107A and HSPD21 for 
London data showing very clear clustering and (b) Scatterplot of PRT 
results for Edinburgh data showing very clear clustering.    
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4.2.2: Application to case-control association studies RI&URKQ¶V 
samples 
4.2.2.1: Genotyping completion and concordance 
Beta defensin genomic copy number was analyzed in 732 samples of 
&URKQ¶V GLVHDVH SDWLHQWV IURP 3URIHVVRU &KULVWRSKHU 0DWKHZ VHFWLRQ
2.1.1.3) and 185 controls (from ECACC panel 1 and 2). Furthermore, a 
total of 350 controls and 384 colonic disease patients received from 
Edinburgh collaborators (section 2.1.1.3) were also genotyped by using the 
same triplex system. For the Edinburgh group, 36 controls and 26 CD 
samples failed to give any genotype, and after removal of the duplicated 
samples in the London group only 666 samples were taken into account, 
from which 18 samples failed to give results. Independent analysis was 
carried out for acceptable results obtained from both groups; 648 cases 
and 185 controls from London samples and 358 cases and 314 samples 
provided by Edinburgh samples. 
 
 Before proceeding to further analysis, several procedures were applied to 
the acceptable results to achieve a high confidence in the results produced 
by triplex system. This began with an inspection of the discordances of 
copy number measurement between different components of the assay in 
the triplex system and/or where the support for the maximum likelihood 
copy number (ML CN) was relatively low. This applied to 48 samples for 
the London group and 51 samples for the Edinburgh cohort. To continue 
with this procedure, the mean of the two PRT results from the triplex assay 
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was calculated and the peak information from 5DELR4 (such as peak ratio 
and number of the peaks) was included in this analysis. Then, ML CN was 
compared to the rounded mean of the two PRTs. If both of them agreed 
between each other then, the ML CN was not changed. Whenever they did 
not agree, investigation of the information from 5DELR4 peak was carried 
out. If the 5DELR4 information had very strong concordance evident either 
with the rounded mean of the two PRTs or with the ML CN, the final copy 
number followed the one that agreed with 5DELR4. Whenever neither of 
them (rounded mean of two PRT nor ML CN) was consistent with the 
5DELR4 information, analysis of two microsatellites, (EPEV1 and EPEV3) 
(section 2.4) was carried out on 35 of 99 samples in order to clarify the 
correct copy number. Allele ratios from microsatellite analyses were used 
as the final criterion in this procedure. Strong evidence from microsatellites 
to support any of the results from ML CN, rounded mean of the two PRTs 
or 5DELR4 was taken into account to alter the ML CN. If none of the above 
gave strong evidence to support changing the ML CN, then the ML CN was 
unchanged. As a result, there were 20 cases of altered copy number in this 
study.   
 
Then analysis of the accuracy of beta defensin copy number measurement 
by this system was made by looking at the clustering of two PRT assays as 
shown in figure 35. As before, clustering around integer copy numbers of 
2, 3, 4, 5, 6 and 7 in the two cohort studies has been clearly produced. In 
this study, the initially calibrated distributions for PRT107A values in cases 
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from both cohorts, and controls from the Edinburgh collection was not 
clustered exactly on the integer values (Figure 36); by contrast, the 
ECACC samples used as controls for the London-based cases showed no 
such shift in the centre of PRT107A clusters (Figure 37). This implies the 
sensitivity of copy number values measured by PRT107A to differences in 
DNA preparation methods. Therefore, to avoid propagating errors into 
further analyses, a linear transformation was applied to all PRT107A 





Figure 35: Results produced by two PRT assays (PRT107A and HSPD21) 
in the triplex system for two different cohorts; London and Edinburgh. (a) 
Scatterplot of triplex results that agree between PRT107A and HSPD21 for 
samples received from London showing very clear clustering and (b) 
Scatterplot of PRT results for samples received from Edinburgh showing 





Figure 36: Initial results produced by two PRT assays (PRT107A and 
HSPD21) in the triplex system for two different cohorts; Edinburgh and 
London before a linear adjustment. (a) Scatterplot of triplex results that 
showing PRT107A values shifted from the integer copy number compared 
to HSPD21 values for samples received from London and (b) Scatterplot of 
PRT107A results for samples received from Edinburgh showing a similar 
shifted compared to HSPD21. 
 143 
 
Figure 37: Initial results produced by two PRT assays (PRT107A and 
HSPD21) in the triplex system for ECACC panel 1 and 2 used as controls 
IRU&URKQ¶VGLVHDVHDnalyses from London samples. No shift of PRT107A 
values compared to HSPD21 is seen for the ECACC controls.  
 
Another way to show the accuracy of the copy number measurement, 
namely examination of the frequency distribution of copy number 
measured by triplex system, was carried out; a histogram of the unrounded 
mean PRT, which was calculated from both PRT (PRT107A and HSPD21) 
was plotted for both cohorts as shown in figure 38. In both cases, it clearly 
showed the grouping of data around each integer copy number even 
though there was no clear gap between each copy number division; rather, 
there was an overlap with each division at the end of the left and right 
sides for each copy number group.  
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The PRT107A values appeared to show quite a spread at each end of the 
distribution for certain samples in both cohorts (Figure 39(a) and 40(a)) in 
nearly all the groups of copy numbers compared to the HSPD21 values 
which produced tighter distributions for each copy number (Figure 39(b) 
and 40(b)). As explained in section 4.2.1, this is perhaps due to differences 
in the batches of sample preparation, some small degree of amplification 
from another chromosome (chromosome 2 which only has one mismatch) 
or not enough amplification from the copy number variable locus. As a 
result, the PRT107A values for certain samples did not achieve the correct 
copy number. Thus, distributions of copy number from unrounded mean 
PRTs overlapped between clusters for copy number of three, four and five 
(Figures 39(c) and 40(c)).  
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Figure 38: Histogram of unrounded mean PRT calculated from both 
PRT107A and HSPD21 from two different cohorts. (a) Distribution of mean 
PRT for each copy number showing very clear clustering in the London 
group. (b) Distribution of mean PRT for each copy number also showing 




Figure 39: Distribution of each copy number from London samples 
coloured according to final ML CN value. (a) Distributions of PRT107A 
values for each copy number. (b) Distributions of HSPD21 for each copy 
number. (c) Distributions of each copy number from unrounded mean PRT. 
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Figure 40: Distribution of each copy number from Edinburgh samples 
coloured according to final ML CN. (a) Distributions of PRT107A values for 
each copy number. (b) Distributions of HSPD21 for each copy number. (c) 
Distributions of each copy number from unrounded mean PRT excluded 
two samples which correspond to the copy number of 1 and 9. 
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In this study, 821 Edinburgh samples were additionally typed using real-
time PCR methods by Marian C. Aldhous (Edinburgh collaborator). 
Analysis of clustering around integer values from real-time PCR gave a 
strong correlation between the two methods. However, it also produced a 
wide range of overlap between results from neighbouring integer copy 
number (Figure 41), in contrast to the results from PRT shown in figure 
35(b) with a distinct clustering around integer values.  Distribution of 
unrounded mean copy number from both methods of real-time PCR was 
also plotted in order to examine the clustering of each copy number (Figure 
42). Neither Def: ct nor Def:Alb showed clear grouping for each copy 
number. 


























Figure 41: Scatterplot produced by two methods of real-time PCR assay 




Figure 42: Histogram of unrounded mean copy number of duplicated 
typing calculated from both methods of real-time PCR; standard-curve 
Albumin and ct. (a) Distribution for each copy number from ct (b) 
Distribution for each copy number from standard-curve controls. 
 
Of 821 samples, there were 625 (322 case and 302 control samples) for 
which CNV measurement data were obtained on the same DNA samples 
both from real-time PCR and the PRT-based triplex assay. Either using the 
values from ct or standard curve methods of real-time PCR, clustering 
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around integer values from those samples showed a wide spread, in which 
some results from real-time PCR fell outside the integer range of each 
copy number (Figure 43). Concordances between two assays (PRT-based 
triplex assay and real-time PCR (both methods)) for those 625 samples 
were also examined, with only 44% of integer copy number values from 
ct and 47% from standard curve analyses from real-time PCR 
measurements agreeing with corresponding integers deduced from the 
triplex assay.   
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Figure 43: Comparison of results between two PRT assays (PRT107A and 
HSPD21) in the triplex system with real-time PCR data obtained from 
Edinburgh collaborators. (a) Scatterplot of results comparing mean PRT 
and standard-curve method of real-time PCR showing very broad range 
which some results from real-time PCR is falling outside the cluster for 
each copy number and (b) Scatterplot of mean PRT and ct of real-time 
PCR results showing small improvement in clustering of raw real-time PCR 
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data but still with much of the data from real-time PCR falling outside the 
clusters.   
 
4.2.2.2: Association results  
By using the triplex PRT-based assay, this study found that the beta-
defensin copy number varied between two to eight copies per diploid 
genome in controls and two to nine copies between colonic disease (CD) 
cohort (figure 44(a)) for the London group. For the Edinburgh group, 
between one to nine copies for controls and two to eight copies for CD 
cases (Figure 44(b)). There was no significant association determined 
between beta-GHIHQVLQFRS\QXPEHUDQG&URKQ¶VGLVHDVHIRU WKH/RQGRQ
samples with the T-test P value calculated as 0.489 (Figure 44(a)). 
However, due to an increased frequency of 5-copy samples among 
&URKQ¶V SDWLHQWV LQ (GLQEXUJK VDPSOHV WKHPHan copy number between 
controls (4.236) and cases (4.397) appeared to be slightly elevated, with 
the T-test P value given as 0.049. A similar increase of mean copy number 
relative to controls was detected using ct analysis of real-time PCR data 
which was 3.64 for controls and 3.82 for cases (Figure 45(a)) with a T-test 
P value of 0.025. However, there was no evidence of increasing mean 
copy number relative to the controls in standard-curve analysis of the same 
samples, (mean copy number for controls was 3.65 and 3.75 for cases (T-
test P value = 0.248) (Figure 45(b)). Additionally, the same 303 control 
DNA samples from both assays (PRT-based triplex and real-time PCR) 
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were compared, and the PRT-based triplex data had a mean copy number 
of 4.23, but the same samples have a mean of 3.79 with real-time 
PCR/ ct (T-test P value = 1.26x10-5). This analysis suggests that real-
time PCR methods could introduce an error in copy number typing 









Figure 44: Distribution of copy number values from the PRT-based triplex 
assay. (a) Comparison of copy number frequency between ECACC 
controls and cases from London samples (the P-value is 0.489) and (b) 
comparison of copy number frequency between controls and cases from 
Edinburgh samples (the P-value is 0.049).   
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Figure 45: Distribution of copy number values from the real-time PCR 
methods for Edinburgh samples. (a) Comparison of copy number 
frequency between controls and cases obtained from ct method (P = 
0.025) and (b) comparison of copy number frequency between controls 




Furthermore, there were no significant associations determined between 
beta-defensin copy number either in colonic or ileal samples for the 
London samples with the T-test P value calculated as 0.704 (Figure 46 (a)) 
and 0.403 (Figure 46 (b)) respectively. A similar finding of no significant 
association for beta-defensin copy number on colonic and ileal samples 
from Edinburgh with the T-test P value were 0.445 (Figure 47 (a)) and 
0.439 (Figure 47 (b)) respectively. Nevertheless, due to an increased 
frequency of 5-FRS\ VDPSOHV DPRQJ &URKQ¶V SDWLHQWV LQ SRROHG LOHDO
samples, the mean copy number between controls (4.305) and ileal 
samples (4.467) appeared to be slightly elevated, with the T-test P value 




Figure 46: Distribution of copy number values from the PRT-based triplex 
assay in London group. (a) Comparison of copy number frequency 
between ECACC controls and colonic samples with a P-value of 0.704 and 
(b) comparison of copy number frequency between controls and ileal 




Figure 47: Distribution of copy number values from the PRT-based triplex 
assay in Edinburgh group. (a) Comparison of copy number frequency 
between controls and colonic samples (P = 0.445) and (b) comparison of 
copy number frequency between controls and ileal samples with a P-value 
of 0.439.   
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Figure 48: Distribution of copy number values from the PRT-based triplex 
assay IRUERWK W\SHVRI&URKQ¶VGLVHDVH (a) Comparison of copy number 
frequency between pooled controls and pooled colonic samples from 
London and Edinburgh groups (P = 0.113) and (b) comparison of copy 
number frequency between pooled controls and pooled ileal samples from 





This study aimed to develop an efficient and powerful method to accurately 
measure beta-defensin copy number variation suitable for large case-
control association studies. All the analyses revealed that the PRT-based 
triplex assay which has been used to measure beta defensin copy number 
LQ &URKQ¶V GLVHDVH LQ WKLV VWXG\ LV DQ DFFXUDWH PHWKRG WKDW PHHWV WKH
above criteria. Reproducibility of the results was investigated by repeated 
testing of internal reference samples in which the beta-defensin copy 
number was known from other typing methods and showed a clustering 
around integer values (section 4.2.1, figure 34), and suggested a high 
standard of precision for this triplex assay with a per-test error rate of the 
order of 3-4%. Therefore, calibrating each copy number produced from the 
&URKQ¶V GLVHDVH VDPSOHV WR WKH FHQWres of these clusters (Figure 35) 
overcame potential accuracy differences between experiments. This 
clustering enabled the final copy number identification and resulted in six 
distinct clusters between two and seven gene copies per diploid genome.     
 
Furthermore, this study has also provided evidence for the power of copy 
number measurements that comes from combining methods and repeat 
typing (Hollox et al., 2008), even though the reference locus of the 
PRT107A assay appeared to include small degree of amplification from 
another chromosome (chromosome 2) which only has one mismatch, and 
which would result in a reduced copy number value in the affected system, 
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but would not affect the other two assays (HSPD21 and 5DELR4). 
&RQYHUVHO\ WKHUH LV DOVR QR VLJQLILFDQW HYLGHQFH RI µGURS-RXW¶ RI RQH RU
more copies of the reference locus that would lead to apparent doubling of 
the copy number of the test locus (Armour et al., 2007), and neither of two 
PRT assay results showed a discrepancy of exactly double the consensus 
value. Multiplex PRT was firstly described by Walker et al. (2009), who 
used three combinations of PRT systems to measure copy number at 
CCL3L1 and CCL4L1 genes. They demonstrated that this multiplex PRT 
produces accurate and reproducible data in the copy number range 
common in Europe but that a further development is necessary for a robust 
typing system for samples of African origin, in which copy numbers of 
CCL3L1 appear to range as high as 14 (Walker et al., 2009).     
 
Comparison of integer clustering between ECACC (panel 1 and 2) and 
non-ECACC samples (London cases and Edinburgh controls and cases) 
(Figure 36 and 37) on the initial results (before linear adjustment has been 
carried out effectively) showed that different methods of DNA preparation 
could make a difference to the typing copy number. This experience has 
reinforced the idea that great care should be taken throughout the 
investigation in case-control association studies using multiallelic copy 
number variants (McCarroll, 2008). Moreover, side-by-side typing of beta-
defensin copy number variation by two methods on the same samples that 
produced different results might also be evidence for influence from 
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different methods of DNA preparation and perhaps, the storage and 
handling of DNA samples (Clayton et al., 2005).  
 
The comparison between our PRT-based triplex assay and real-time PCR 
results from the same samples (Figure 43) strongly suggests that real-time 
PCR measurements are insufficiently accurate for reliable copy number 
variable typing. There is a high correlation between the two real-time PCR 
results despite the low accuracy of copy number typing which is actually 
subject to measurement error of sufficient magnitude to obscure the 
resolution of results into integer-centred copy number classes (Figure 41), 
as is also apparent from the general failure of real-time PCR methods to 
resolve copy number cluster clearly for N > 2 at the CCL3L1 copy number 
variant (Field et al., 2009).  
 
Obviously, our results from the PRT-based triplex assay do not provide 
strong support for the finding of Bentley et al. (2009) that there is a 
significantly increased beta-GHIHQVLQFRS\QXPEHUDPRQJ&URKQ¶VGLVHDVH
patients. The investigators found a mean increase in copy number of 0.41 
repeats among affected individuals of European origin from New Zealand 
with a mean copy number of 4.36 in cases and 3.95 in controls (Bentley et 
al., 2009). Their findings contrast with this study that found no clear 
increase in mean copy number in either cohorts, London and Edinburgh 
(4.48 for cases and 4.42 for controls) and (4.40 for cases and 4.24 for 
controls) respectively. Certainly, this work is in addition unable to provide 
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any support for the conclusions of Fellermann et al. (2006), that the copy 
number of beta-GHIHQVLQV LQ &URKQ¶V GLVHDVH RI WKH FRORQ LV VLJQLILFDQWO\
reduced (Fellermann et al., 2006). Both of the previous studies Bentley et 
al. and Fellermann et al. depended on real-time PCR methods for 
analysing beta-defensin copy number (Fellermann et al., 2006; Bentley et 
al., 2009). AQDO\VLV EHWZHHQ GLIIHUHQW SKHQRW\SHV RI &URKQ¶V GLVHDVH in 
this study also do not illustrate any genuine association of the beta-
defensin copy number either with FRORQLFRULOHDO&URKQ¶VGLVHDVH 
 
4.4: Conclusion 
In conclusion, the PRT-based triplex assay, which has been successfully 
applied in this study, is an accurate and robust method that would be 
sufficiently accurate for measuring copy number variation in large case-
control association studies. Even though this assay contains three 
components - two PRTs (PRT107A and HPD21) and a multi-allelic indel 
(rs5889219) measure, it uses a single capillary electrophoresis column per 
sample, and so this PRT-based triplex assay remains simple and 
inexpensive in practice for investigation of a single copy number variable 
locus in a large sample set. Without any doubt the copy number values 
produced from these three components has increased the power of copy 
number measurement of the beta-defensin variation. This assay has 
illustrated strong reliability in the quantification of low copy number to high 
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copy number (two to seven copies) by clear clustering and its ability to 


















Chapter 5: General Discussion and Conclusion 
 
5.1: Origins of diversity at human beta defensin  
copy number  
In chapter three, copy numbers of the human beta-defensin repeat 
between two and eight copies per diploid genome were identified in 26 
CEPH families originating from European populations; there were one to 
five copies of the locus per haploid genome, with two and three copies 
being the most common. Pedigree analyses within CEPH kindreds in this 
study allowed us to trace the origin of parental haplotypes of these beta-
defensin copy numbers. Moreover, the origin of this copy number variation 
has been discovered by investigation of recombinant haplotypes inherited 
in children and is due to simple allelic crossing-over events between 
homologous chromosomes during meiosis. As discussed in section 1.1.4 
and illustrated in figure 3, the chromosome 8p23.1 region is flanked by two 
highly homologous sequences of low copy repeats (LCRs) or segmental 
duplications (SDs) named REPD distally and REPP proximally. The beta-
defensin gene clusters located on chromosome 8p23.1 that are annotated 
on the genome assembly are found to be flanked with low copy repeats 
(LCRs) distally (REPD). SD blocks are known to act as mediators for the 
exchange of DNA sequence through non-allelic homologous recombination 
(NAHR) from many examples involved with duplications and deletions 
associated with genomic disorders, for example, the alpha-globin locus 
 166 
(Higgs et al., 1989), PMP22 genes (Reiter et al., 1998), the RHD genes 
(Wagner and Flegel, 2000) and genes which encode for colour vision 
variation (Deeb, 2004) and even deletion and reciprocal duplication of 
8p23.1 (Giglio et al., 2001).  
 
Subsequently in this study, allelic recombination events discovered from 
segregation of copy number, microsatellite and multiallelic length 
polymorphism (indels) in the pedigree analyses, together with linkage 
analysis of other markers in this region has revealed the beta-defensin 
gene clusters in two different locations including a new placement near 
REPP, about 5 Mb away from the distal location, REPD. The precise 
crossing-over points between the two parental haplotypes in 24 LQGLYLGXDO¶V
recombinant haplotypes are placed within the interval corresponding to the 
8p23.1 region, but all the beta-defensin genes were consistently mapped 
either onto the accepted location at REPD or to another site close to 
REPP, the proximal set of SDs on 8p23.1. 
 
Construction of the haplotype blocks from the sequence variants is 
essential to distinguish the beta-defensin repeats between two sites at 
REPD and REPP. Comparisons of sequence reads from recombinant 
CEPH families to the reference sequence genome have shown that 
inversion events might contribute to the exchange of the beta-defensin 
locations since the identical sequence haplotypes have been observed at 
both sites (table 10). The inversion polymorphism between REPD and 
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REPP in the chromosome band 8p23.1 region has been well documented 
from previous studies. Nevertheless, none of the previous studies has 
considered information about the beta-defensin clusters at the REPP sites. 
Investigation of the exact breakpoint of the inversion polymorphism, which 
may include the beta-defensin region, is a challenging problem because 
these repeats are situated in a complex segmental duplication (REPD). 
These duplications have been separated by a gap in the assembled 
sequence, and only with evidence from recombinant haplotypes could this 
copy number variable region be placed at REPP. The other problem is 
there could be several different types of inverted alleles with different 
precise breakpoints.  
 
Furthermore, the beta-defensin copy number seems to be more variable 
proximally (REPP) than distally (REPD) as demonstrated in table 7. Thus, 
investigation of copy number variation by using a single nucleotide 
polymorphism close to the accepted REPD location might not show an 
association with copy number variation. A proper analysis of the sequence 
variants for the whole repeat at both sites may provide important 
information on the possibility of using linkage disequilibrium (LD) with 
SNPs to predict copy number at the beta-defensin region. Such structural 
genomic variation involving the beta-defensin gene clusters has provided 
us insight into the origin for diversity of copy number. In general, this study 
has contributed valuable information on the beta-defensin mapping in the 
human genome and human chromosome evolution, based on family 
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analysis. Moreover, this finding could lead to the development of more 
efficient strategies to identify copy number variants within this complex 
region that are suspected to have clinical consequences.   
 
5.2: Development of a multiplex PRT measurement  
system for beta-defensin copy number variants  
In chapter four, a multiplex PRT measurement system was applied to 
accurately measure the multiallelic copy number polymorphism of the beta-
defensin region. The process of defining and mapping CNVs has been 
facilitated by many methods. These include array-based CGH using 
oligonucleotides and bacterial artificial chromosome clones, comparison of 
clone paired-end sequence to the reference human assembly and 
detection of deletions and duplications based on single nucleotides 
polymorphisms (Iafrate et al., 2004; Tuzun et al., 2005; Redon et al., 2006; 
Kidd et al., 2008). However, these methods provide very little information in 
complex regions of copy number variation. Nowadays, investigating 
association between the possessions of common variants, for example, 
copy number changes and/or SNPs, and particular traits by using such 
high throughput methods has been the source of many discoveries about 
disease causation (McCarroll et al., 2008). Nevertheless, simple, 
inexpensive, and accurate analysis measurements are still in demand 
particularly for the most challenging regions such as the beta-defensin 
genes. Results shown in chapter four have proved that this new system is 
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highly capable in classifying samples into a distinct (integer) copy number 
(figure 35), ranging from two to seven copies and possibly up to nine 
copies (figures 39 and 40). In addition, the beta-defensin copy numbers 
given by all the three methods in this system, are generally in concordance 
as described in section 4.2.2.1. Thus, in this study, assessment of our new 
measurement system based on PRT assays, with indel ratio measurement 
as a complementary method, have demonstrated highly accurate 
prediction of the beta-defensin copy number in an association study, 
especially when directly compared to RT-PCR. Perne et al. (2009) found in 
their study that two quantification methods, real-time PCR and MLPA were 
affected similarly by decreased reliability in the discrimination of higher 
copy numbers. Other studies on CCL3L1 copy number determination 
highlighted the technical difficulty of obtaining convincingly accurate copy 
number measurements using methods based on real-time PCR, even in 
the relatively low copy number range of those CNV genes (Field et al., 
2009). Field et al. (2009) found a difference for an apparently significant 
association between the data from the same samples (several thousand 
cases and controls in a study of type I diabetes), using either real-time 
PCR or assays using the Paralogue Ratio Test (PRT). There was an 
apparently highly significant association between CCL3L1 copy number 
and type I diabetes using real-time PCR data but no association with type I 
diabetes was replicated by PRT-based measurement of copy number 
(Field et al., 2009).  
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Association studies based on a candidate gene is one very well known 
approach to examine the relationship between variation at a gene and 
predisposition to a multifactorial disease, for example Crohn¶V GLVHDVH. 
&URKQ¶V GLVHDVH KDV SURYLGHG D UHPDUNDEOH H[DPSOH LQ GHILQLQJ WKH
genetic factors responsible for the observed clinical phenotype (Van 
Limbergen et al., 2009). However, there are still significant issues when 
attempts to replicate association with specific genes and variants have 
failed in different kind of observations; for example, different measurement 
methods may have different accuracy and resolution, and there may be 
variation in the source and phenotype identity of the samples. Thus, the 
illustration of the beta-defensin copy number variable region may provide 
important understanding of WKH &URKQ¶V GLVHDVH SDWKRJHQHVLV DQG
individual susceptibility in particular, and more generally application of 
multiallelic copy-number variants in case-control association studies. In 
order to examine association of copy number variants with the disease, an 
accurate assay was needed in order to measure precisely what is the 
correct copy number of the genes involved and to report any real 
relationship with the exact range of the copy number of the gene.  
 
In this study, we have demonstrated our new system is a robust technique 
to determine the association of the beta-defensin genes iQ &URKQ¶V
disease. Small sample sizes are a common shortcoming of association 
studies. For example, our finding using more than 1000 samples did not 
provide any strong support for association reported from previous studies 
 171 
that have highlighted an association of lower beta-defensin copy number 
with a small number of  FRORQLF &URKQ¶V SDWLHQWV DQG  FRQWUROV
(Fellermann et al., 2006), and only weak support, for the association with 
higher copy number reported by Bentley et al. (2009). Minimizing 
heterogeneity between studies for example, variation within a phenotype 
related to aetiology, is important to maximize the chances of success. 
Investigations using the large samples size and clearly identified 
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